Biopharmaceutical benchmarks 2018

Gary Walsh

Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.

ntibodies continue to dominate biopharmaceutical approvals, but new nucleic acid modalities and cellular therapies are also slowly launching on the market. This article provides an update on three previous surveys of biopharmaceutical approvals¹⁻³. The current survey period (January 2014 to July 2018) witnessed the approval of 155 biopharmaceutical products (see Table 1 for definition) in the United States and/or European Union, when counted by product trade name. Some products contain identical active ingredients or are sold under different trade names in the two regions. Taking this into account, 129 distinct biopharmaceutical active ingredients entered the market.

With these new approvals, the number of individual biopharmaceutical products having gained a license in these regions now totals 374, containing 285 distinct active biopharmaceutical ingredients. However, over the years, 58 products have been withdrawn from the market following approval in one or both regions, almost always for commercial reasons. When withdrawals are taken into account, the number of individual biopharmaceutical products with current active licenses stands at 316 (**Table 1**).

Annual approval numbers over the current survey period ranged from a low of 14 in Europe in 2014 to a high of 36, also in Europe, in 2017 (**Fig. 1a**). Products approved over the four and a half years include 68 mAbs, 23 hormones, 16 clotting factors, 9 enzymes, 7 vaccines, 5 nucleic acid–based products and 4 engineered cell–based products. As this study period was coming to a close, the first RNA interference (RNAi) drug was approved in the United States.

Gary Walsh is in the Industrial Biochemistry Program, Department of Chemical Sciences and Bernal Institute, University of Limerick, Ireland. e-mail: gary.walsh@ul.ie




Figure 1 Product approvals profile. (a) Annual product approval numbers (by product trade name) by individual region. (b) Number of product approvals in one or both regions over the indicated periods.

Here I list all recombinant biologics approved during the past four and a half years (from January 2014 to July 2018), examining the types of biopharmaceutical drugs that have reached the US and EU markets as well as the indications for which they are registered. As in previous articles^{1–3}, I have not included tissue-engineering products, which the US Food and Drug Administration (FDA) classifies as pure medical devices.

In a snapshot

Overall, new approvals followed relatively predictable lines, with cancer representing the single most common indication (33 products). Other common indications included various inflammation-related conditions (24 products), hemophilia (16 products) and diabetes (15 products). Approvals for other indications, less commonly targeted by biopharmaceuticals, included asthma, migraine, HIV and inhalational anthrax.

Of the 155 individual biopharmaceutical products approved, 81 (52%) were genuinely new to the market, with the remaining products representing biosimilars, me-too products, and products previously approved elsewhere. Those 81 new products (by trade name) contained a total of 71 distinct active biopharmaceutical ingredients (**Table 2**). Looking at each region independently, 97 products were licensed in the United States in the survey timeframe while 109 products gained marketing authorization in the European Union.

In the same period, US regulators approved a grand total of 207 products containing novel molecular (chemical or biological) entities, indicating that 47% of all genuinely new drug approvals in the US were biopharmaceuticals. This represents a substantial increase over values reported in our previous surveys in 2010 and 2014 (21% and 26%, respectively)^{1,2}, but tallies well with data presented in our 2006 survey³, which estimated that some 44% of all drugs in the then developmental pipeline were biotech-based. Ambiguity in EU data reporting structures precludes calculation of an analogous figure for Europe.

Overall trends

Comparing approvals over the current survey period with those in earlier periods, or with cumulative approvals, reveals interesting, if not somewhat predictable, trends. Approval numbers in each five-year period from 1995 until 2014 have remained remarkably constant (54-60 approvals; Fig. 1b). However, approvals have accelerated markedly since that time. The past three and a half years alone (January 2015 to July 2018) have seen 112 (Fig. 1b) product approvals-essentially double the typical five-yearly historical approval pace. Although a wave of biosimilar approvals contributed to this trend, the number of genuinely novel approved products hasn't lagged far behind: such drugs represented 52% of approvals in the past four and a half years compared with 59% in the period 2010 to 2014 (ref. 1).

The era of the antibody is upon us

The data also show an increasing dominance of mAbs within the universe of biopharmaceutical approvals. Although they represented just over a quarter (27%) of all first-time approvals from 2010 to 2014, they comprise over half (53%) of first time approvals from 2015 to July 2018 (**Fig. 2a**).
 Table 2 Biopharmaceuticals approved in the US and/or EU January 2014–July 2018

 by category

Category	Products (by trade name)					
Genuinely new biopharmaceuticals	Adynovi/Adynovate, Vonvendi, Obizur, Elocta/Eloctate, Andexxa, Rebinyn/ Refixia, Alprolix, Idelvion, Suliqua/Soliqua, Xultophy, Myalepta/Myalept, Ozempic, Eperzan/Tanzeum, Trulicity, Oxervate, Plegridy, Shingrix, Trumenba, pandemic influenza vaccine H5N1, Mosquirix, Aimovig, Crysvita, Fasenra, Hemlibra, Ilumya, Trogarzo, Bavencio, Besponsa, dinutuximab beta Apeiron/ Qarziba, Dupixent, Imfinzi, Kevzara, Kyntheum/Siliq, Rituxan Hycela, Tecentriq, Tremfya, Zinplava, Anthim, Cinqair/Cinqaero, Darzalex, Empliciti, Lartruvo, Taltz, Blincyto, Cosentyx, Keytruda, Nivolumab BMS ^a /Opdivo, Nucala, Praluent, Praxbind, Repatha, Unituxin ^a , Cyramza, Entyvio, Sylvant, Palynziq, Lamzede, Brineura, Mepsevii, Kanuma, Strensiq, Vimizim, Tegsedi, Luxturna, Spinraza, Exondys 51, Imlygic, Alofisel, Kymriah, Yescarta, Strimvelis, Zalmoxis					
Biosimilars	Semglee, insulin lispro Sanofi, Lusduna, Abasaglar/Basaglar, Bemfola, Movymia/ Terrosa, Retacrit ^b , Fulphila, Nivestym/Nivestim ^b , Zarxio ^b , Accofil, Halimatoz/ Hefiya/Hyrimoz, Herzuma, Kanjinti, Mvasi, Trazimera, Zessly, Amgevita/ Amjevita/Solymbic, Blitzima/Truxima/Ritemvia/Rituzena, Cyltezo, Imraldi, Ixifi, Ogivri, Ontruzant, Renflexis/Flixabi, Rixathon/Riximyo, Inflectra/Remsima ^b , Erelzi, Benepali					
Reformulated, me-too, different indication, and related	Afstyla, Vihuma/Nuwiq, Iblias/Kovaltry, Ixinity, Admelog, Fiasp, Toujeo, Afrezza, Rekovelle, Natpara, Natpar, Saxenda, Ristempa ^a , Heplisav-b, Gardasil 9, Ocrevus, Portrazza, Zinbryta ^a , Oncaspar, Lifmior, Spectrila					
Previously approved elsewhere	Rixubis, Ruconest, Ryzodeg 70-30/Ryzodeg, Tresiba, Bexsero, Mylotarg, Gazyva/ Gazyvaro					
	^a Products were both approved and subsequently withdrawn from one or both regions within the survey timeframe. ^b Biosimilars approved in one region since 2014, but which were approved in the other region before 2014.					

The relative importance of mAbs in terms of the percentage of overall biopharmaceutical product sales also continues to grow steadily (**Fig. 2b**), although not so dramatically as product approval numbers might imply. However, antibody sales, both in terms of absolute value and as a percentage of overall biopharmaceutical sales, will likely continue to increase, particularly as revenues derived from the recent glut of mAb approvals grow toward maximum market value.

Notably, approvals of gene- and other nucleic acid–based products (antisense oligonucleotides (ASOs) and gene therapies, including gene-engineered cells) increased as well during this period. The number of nucleic acid and cell-based products approved in the period totaled nine, five nucleic acid and four engineered cells (**Table 1**).


The period of this study also witnessed a pickup in approvals of some traditional product classes as compared with previous study periods, notably clotting factors (**Box 1**) and some hormones, although approvals of most traditional product classes continued to drop off. For example, no recombinant thrombolytic agent, anticoagulant, interleukin or human growth hormone has been approved since 2014, and only one interferon and one erythropoietin were approved. This continued trend likely reflects market saturation relative to demand for these products.


Another continuing trend is the increased prominence of mammalian over nonmammalian expression systems used for producing approved products (Fig. 3). In fact,

the trend toward mammalian cell lines has accelerated dramatically in the past three to four years. Sixty-two of the 71 genuinely new biopharmaceutical active ingredients that have come on the market in the survey period (Table 2) are recombinant proteins. Of those, 52 (84%) are expressed in mammalian cell lines, one (Kanuma, sebelipase alfa) is expressed in a mammalian transgenic system, and the remaining nine are produced using Escherichia coli (five products) or yeast (four products), all in S. cerevisiae. The surge in mammalian-based production is unsurprising, given the many recent mAb and clotting factor product approvals, with both product classes bearing post-translational modifications and thus requiring mammalian expression systems.

Chinese hamster ovary (CHO) cell-based systems remain by far the most common mammalian cell line in use; 84% (57 of the 68 mAb products approved in the current survey period) are produced in CHO systems, with the remaining antibodies approved produced in either NS0 cells (nine products) or Sp2/0 cells (two products). Overall, recent approvals (**Tables 1** and **2**) also confirm that there is little industrial enthusiasm for exploring new expression systems.

The current survey period has also been characterized by a continual rise in the market value of biopharmaceuticals. Data from various La Merie financial reports indicate that cumulative sales over 2014–2017 reached \$651 billion, whereas total sales for 2017 alone reached \$188 billion (http://www.lamerie.com)⁴.







The mAb Humira (adalimumab) has been by far the single most lucrative product each year during the survey period, having generated global sales just short of \$19 billion in 2017 and \$62.6 billion cumulatively between 2014 and 2017 (**Table 3**). The top ten selling biopharmaceuticals together generated sales of \$80.2 billion in 2017, representing almost 44% of total biopharmaceutical product revenues. Forty-five individual biopharmaceutical products recorded 'blockbuster' status sales (>\$1 billion) last year.

mAbs continue to represent the most lucrative single product class. Total mAb sales (including Fc fusion protein–based antibodylike traps) reached \$123 billion last year (\$103.4 billion if fusion products are excluded). Moreover, mAbs represented eight of the top ten products by sales in 2017 (six of the top ten if the fusion traps are excluded). In terms of target indications, the vast majority of antibody or antibody-like trap fusion products target inflammatory, autoimmune conditions (cumulative 2017 sales of \$64.6 billion, with products targeting tumor necrosis factor (TNF)- α alone generating \$39.8 billion) and cancer (2017 cumulative sales of \$43.1 billion). In terms of non-antibody-based products, insulins are the next most lucrative product class, collectively generating sales of \$22 billion in 2017.

Biosimilars blossom

The survey period witnessed a surge in biosimilar approvals, signaling that this class of product is maturing. When considered by product trade name, 52 biosimilars have gained approval in the European Union and/ or the United States since 2006 (**Table 4**), although 3 were subsequently withdrawn for commercial reasons.

By product category, the majority of biosimilar product approvals were antibody based (27 of 52), with 10 approvals of granulocyte colony stimulating factor (G-CSF) biosimilars and single-digit approvals of all others. The 52 licensed biosimilar products are actually based on 34 distinct active ingredients (**Table 4**). For example, the four rituximab-based biosimilars approved in Europe in 2017 (under the trade names Blitzima, Truxima, Ritemvia and Rituzena) all contain the same active substance: Celltrion's biosimilar rituximab, developed as CT-P10.

By region, 48 biosimilar products have received marketing authorization in the European Union, with 31 of these (65%) having gained authorization in the current survey period. In the United States, far fewer (13) biosimilars gained a license, the first being Zarzio (filgrastim-sndz) in March 2015, with the first biosimilar mAb (Inflectra; infliximab-dyyb) gaining approval in April 2016. This geographical discrepancy is unsurprising, given that the EU biosimilar regulatory framework (including the underpinning legislation and follow-on regulatory guidelines) pre-dates the US regulatory framework by almost a decade.

Of the 52 biosimilars approved thus far, two-thirds (35) are first-time approvals since 2014. This period witnessed few approvals of 'traditional' biosimilars, unlike earlier periods, in which most biosimilars approved were human growth hormone, erythropoietin or G-CSF products. Since 2014, approvals of these biosimilars have invariably been approvals in the United States of products previously approved in the EU. In recent years, the focus of approvals has shifted toward engineered insulins (4 approvals) and mAbs (25 product approvals; Table 4). Drivers here are market value, coupled with patent expiry and the availability of analytical methodology capable of demonstrating structural similarity in the context of proteins as large and complex as mAbs (Box 2). The survey period has therefore witnessed the approval of a raft of products demonstrating biosimilarity to the top-selling drugs, with biosimilar versions having come on-stream for eight of the top ten global-selling originator products (Table 3).

Biosimilars have achieved a widespread degree of acceptance in the European Union, where several such products have been on the market for over a decade. In that time,

Box 1 Clotting factors

Genetic defects characterized by lowered expression (or altered amino acid sequence) of any clotting factor can compromise the blood clotting process, leading to congenital hemophilia. Characterized by spontaneous and prolonged hemorrhage, hemophilia is due in over 80% of cases to a deficiency in factor VIII activity (hemophilia A), while in most of the remainder it is due to a deficiency in factor IX (hemophilia B). Global incidence of hemophilia is estimated at between 200,000 and 400,000, with hemophilia A having an average incidence of ~2 people per 10,000. Disease severity is linked to the percentage of residual active factor produced by the patient, and the disease is treated via intravenous administration of the missing clotting factor. Before the introduction of clotting factor concentrates in the 1960s, the life expectancy was of the order of 15–25 years. In the early 1980s, before the advent of screening tests of HIV in donated blood, large numbers of hemophiliacs contracted AIDS from clotting factors purified from human plasma. The introduction of recombinant clotting factors beginning in the early 1990s drastically reduced dependence on plasma-derived products, and the 2017 global market value for such recombinant products stood at \$8.5 billion. Treatment costs typically vary from \$30,000 to several hundred thousand dollars annually, depending on condition severity and the development of inhibitory antibodies (which 20–30% of hemophilia A patients can develop).

The current survey period witnessed a surge in clotting factor approvals, with ten factor VIII and six factor IX products coming on-stream, although several share the same active ingredient (**Table 1**). In the main, the products approved either are characterized by manufacturing process improvements over earlier-generation products or are engineered to increase serum half-life. For example, Bayer's Kovaltry/Iblias is essentially an updated Kogenate, a recombinant factor VIII. Unlike Kogenate, Kovaltry/Iblias is produced in a baby hamster kidney (BHK) cell line that also expresses heat shock protein 70, with resulting improvement in recombinant productivity. Moreover, all animal-and human-derived additives have been eliminated from the cell culture and purification processes, and a virus filtration step has been introduced for improved nonenveloped viral clearance robustness.


Clotting factor products are usually administered therapeutically (to control active bleeding) or prophylactically (to reduce frequency of future bleeding events). Administration for therapeutic purposes is tailored to individual circumstance while prophylactic administration of unmodified (first-generation) factors typically occurs three times weekly. Engineering to increase serum half-life has relied on PEGylation (Adynovi/Adynovate and Rebinyn/Refixia), Fc fusion (Elocta/Eloctate and Alprolix) or albumin fusion (Idelvion). Engineering had typically reduced prophylactic administration to twice weekly, and such products would be described by some as biobetter clotting factors.


The current survey period also witnessed the approval of a novel mAb-based product indicated for the prophylaxis of hemophilia A in patients who produce anti–factor VIII antibodies, which neutralize any exogenously administered factor VIII). Hemlibra (emicizumab) is a bispecific IgG, one arm of which binds factor IXa while the other binds factor X, effectively triggering factor VIII–independent clot formation. Market analysts predict Hemlibra may attain blockbuster status (sales above \$1 billion) by 2019, reaching \$4 billion by 2022 (https://clarivate.com/blog/life-sciences-connect/green-light-market-hemlibra-hemophilia-inhibitors-us/).

EU-monitoring systems for safety concerns have not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines, and a decade of clinical experience accrued with these products shows that the approved biosimilars can be used as safely and effectively in all their approved indications as other biological medicines⁵. Acceptance in the United States is not as strong, which is unsurprising given the shorter window of experience with biosimilars.

A 2016 report from consultants IMS Health on the impact of biosimilar competition in the European economic area⁶ identifies EU-wide average price reductions from 8% in the case of anti-TNF biosimilar products to 33-34% savings in the context of erythropoietin and G-CSF biosimilars, relative to reference product pricing the year before biosimilar entrance. Moreover, the report found that biosimilar entry affected not only the price of the relevant reference product, but of the whole product class. Globally, 2017 sales generated cumulatively by all biosimilar reference products reached \$73.3 billion. An interesting although hypothetical calculation suggests savings of up to \$22 billion to global healthcare systems if biosimilar entry drove a 30% savings across the board in relation to all these products.

The development of so-called 'biobetters' represents a potential threat to biosimilar development. A biobetter describes an already approved biopharmaceutical entity altered in some way (e.g., a structural modification or an altered finished product combination or formulation) to improve some aspect of its clinical performance. The current period witnessed the approval of very few such products; mainly, they included novel insulin formulations or combinations (Suliqua/Soliqua and Xultophy; **Table 1**), as well as clotting factors with extended half-lives (**Box 2**). Biobetter development is likely tempered by the fact that such products are treated as a new product from a regulatory perspective.





Rank	Product	Sales, 2017 (\$ billions) ^a	Cumulative sales, 2014–2017 (\$ billions)	Year first approved	Company	Patent expiry ^b	Biosimilar version(s) approved
1	Humira (adalimumab; anti-TNF)	18.94	62.6	2002	AbbVie, Eisai	2016 (US) 2018 (EU)	Halimatoz/Hefiya/Hyrimoz, Amgevita/Amjevita/Solymbic, Cyltezo, Imralo
2	Enbrel (etanercept; anti-TNF)	8.34	35.4	1998	Amgen, Pfizer, Takeda Pharmaceuticals	2015 (EU) 2028 (US)	Erelzi, Benepali
3	Rituxan/MabThera (rituximab; anti-CD20)	7.78	29.1	1997	Roche, Biogen Idec	2013 (EU) 2016 (US)	Blitzima/Truxima, Ritemvia, Rituzena, Rixathon/Riximyo
1	Remicade (infliximab; anti-TNF)	7.77	35.6	1998	Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma	2015 (EU) 2018 (US)	Zessly, Ixifi, Renflexis/Flixabi, Inflectra/ Remsima
5	Herceptin (trastu- zumab; anti-HER2)	7.39	27.1	1998	Roche	2014 (EU) 2019 (US)	Herzuma, Kanjinti, Trazimera, Ogivri, Ontruzant
5	Avastin (bevaci- zumab; anti-VEGF)	7.04	27.0	2004	Roche	2017 (US) 2019 (EU)	Mvasi
7	Lantus (insulin glargine)	6.72	27.4	2000	Sanofi	2014 (EU & US)	Semglee, Lusduna, Abasaglar/Basaglar
3	Eylea (aflibercept; anti-VEGF)	5.93	18.0	2011	Regeneron, Bayer	2020 (EU) 2021 (US)	
)	Opdivo (nivolumab; anti-PD-1 receptor)	5.79	11.4	2014	Bristol-Myers Squibb, Ono Pharmaceutical	2027 (US) 2026 (EU)	
LO	Neulasta (pegfilgrastim)	4.53	20.1	2002	Amgen, Kyowa Hakko Kirin	2014 (US) 2015 (EU)	Fulphila
1	Stelara (ustekinumab; anti-IL-12 & IL-23)	4.01	12.2	2009	Janssen Cilag (Johnson & Johnson)	2023 (US) 2024 (EU)	
12	Keytruda (pembroli- zumab, anti-PD-1)	3.81	5.7	2014	Merck	2036 (US) 2028 (EU)	
13	Prolia/Xgeva (deno- sumab, anti-RANKL)	3.54	11.6	2010	Amgen	2025 (US) 2022 (EU)	
14	Lucentis (ranibi- zumab; anti-VEGF)	3.38	14.3	2006	Roche, Novartis	2016 (EU & US)	
15	Novolog/Novorapid (insulin aspart)	3.31	11.7	1999	Novo Nordisk	2015 (EU & US)	
.6	Soliris (eculizumab; anti–C5 complement protein)	3.14	10.7	2007	Alexion Pharmaceuticals	2021 (US) 2020 (EU)	
L7	Simponi (golimumab; anti-TNF)	2.94	9.7	2009	Merck, Janssen, Mitsubishi Tanabe	2024 (EU & US)	
18	Humalog mix 50:50 (insulin lispro)	2.86	11.3	1996	Eli Lilly	2014 (US) 2015 (EU)	Insulin lispro Sanofi
9	Xolair (omalizumab) anti-IgE	2.75	8.7	2003	Roche, Novartis	2017 (EU & US)	
20	Aranesp/Nesp (darbe- poetin alfa)	2.62	10	2001	Amgen, Kyowa Hakko Kirin	2016 (EU) 2024 (US)	

^aFinancial data from La Merie Business intelligence. ^bPatent data from various sources, including http://www.gabionline.net/Biosimilars/General/Biologicals-patent-expiries. HER2, human epidermal growth factor receptor 2; IgE, immunoglobulin E; IL, interleukin; PD-1, programmed cell death receptor 1; RANKL, receptor activator of nuclear factor- κ B ligand; VEGF, vascular endothelial growth factor.

mAb approvals

The data in our survey underscore the current and increasing dominance of mAbs in the biopharma sector, in terms of overall product approvals, biosimilar approvals and market value. Whereas cancer remains the most common target indication, during the period several products aimed at nontraditional mAb target conditions were approved. These include Aimovig (erenumab), indicated for migraine; Fasenra (benralizumab) and Cinqair/Cinqaero (reslizumab) for asthma; Trogarzo (ibalizumab) for HIV infection; and Anthim (obiltoxaximab) for inhalation anthrax. Also notable was the approval of several anti-interleukin mAbs to treat psoriasis, as opposed to the more traditional anti-TNF products for this indication. The new products include Cosentyx (secukinumab), Ilumya (tildrakizumab-asmn), Kyntheum/Siliq (brodalumab), Tremfya (guselkumab) and Taltz (ixekizumab). Taltz is also unusual in that it is a humanized immunoglobulin G4 (IgG4). It was consequently engineered to contain a serineto-proline substitution (S228P), which reduces the frequency of half-antibody formation or other heterologous antibody combinations sometimes observed with IgG4 antibodies.

It is also notable that all the mAbs approved in the survey period were engineered in some way: virtually all novel antibodies approved are either humanized or fully human. One new antibody–drug conjugate (Besponsa, inotuzumab ozogamicin) made it to market, along with two new bispecific products (Hemlibra, emicizumab/emicizumab-kxwh; Blincyto, blinatumomab; **Boxes 1** and **3**). Tecenetriq (atezolizumab), a mAb against programmed cell death receptor ligand 1 (PD-L1), is unusual in that it contains an amino acid substitution (asparagine to alanine) at position 298, in the CH2 domain of each heavy chain. This substitution prevents antibody glycosylation and thus blocks glycan-dependent Fc-effector functions, which is in turn important in the context

Product type	Biosimilar (trade name)	Year (and region) approved	Reference product	Drug (active ingredient) manufacturer
Somatropin-based				
luman growth	Omnitrope	2006 (EU)	Genotropin	Sandoz (Kundl, Austria)
ormone-based	Valtropin	2006 (EU) Withdrawn 2012	Humatrope	LG Life Sciences (Jeonbuk-do, Republic of Korea)
poetin-based				
poetin-based	Binocrit	2007 (EU)	Eprex/Erypo	Rentschler (Laupheim, Germany) & Lek (Menges, Sloveni
	Epoetin alfa hexal	2007 (EU)	Eprex/Erypo	Rentschler & Lek
	Abseamed	2007 (EU)	Eprex/Erypo	Rentschler & Lek
	Retacrit	2018 (US)	Eprex/Erypo (EU)	Norbitec (Uetersen, Germany)
		2007 (EU)	Epogen/Procrit (US)	Norbitec (Uetersen, Germany)
	Silapo	2007 (EU)	Eprex/Erypo	Norbitec
ilgrastim-based				
G-CSF-based	Ratiograstim	2008 (EU)	Neupogen	Sicor (Vilnius, Lithuania)
	Filgrastim ratiopharm	2008 (EU) Withdrawn 2011	Neupogen	Sicor
	Biograstim	2008 (EU) Withdrawn 2015	Neupogen	Sicor
	Tevagrastim	2008 (EU)	Neupogen	Sicor
	Zarxio (US) Zarzio (EU)	2015 (US) 2009 (EU)	Neupogen	Sandoz (Kundl, Austria)
	Filgrastim hexal	2009 (EU)	Neupogen	Sandoz (Kundl, Austria)
	Nivestym (US) Nivestim (EU)	2018 (US) 2010 (EU)	Neupogen	Hospira (Pfizer) (Zagreb, Croatia)
	Grastofil	2013 (EU)	Neupogen	Intas Biopharmaceuticals (Gujarat, India)
	Accofil	2014 (EU)	Neupogen	Intas Biopharmaceuticals
egfilgrastim-based	Fulphila	2018 (US)	Neulasta	Mylan (Zurich)
ollicle-stimulating horr	none-based			
ollicle-stimulating	Ovaleap	2013 (EU)	Gonal F	Merckle Biotec (Ulm, Germany)
normone-based	Bemfola	2014 (EU)	Gonal F	Polymun Scientific Immunbiologische Forschung (Klosterneuburg, Austria)
nsulin-based				
nsulin glargine–based	Abasaglar	2014 (EU)	Lantus	Lilly del Caribe (Carolina, Puerto Rico, USA) Eli Lilly (Indianapolis)
	Lusduna	2017 (EU) 2017 (US), tentative	Lantus	Merck Sharp & Dohme (Elkton, VA, USA)
	Semglee	2018 (EU)	Lantus	Biocon Nusajaya (Johor, Malaysia)
nsulin lispro-based	Insulin lispro Sanofi	2017 (EU)	Humalog	Sanofi-Aventis (Frankfurt)
nAb-based and related				
nfliximab-based	Inflectra	2016 (US) 2013 (EU)	Remicade	Celltrion (Incheon, Republic of Korea)
	Remsima	2013 (EU)	Remicade	Celltrion
	Flixabi	2016 (EU)	Remicade	Biogen (Hillerod, Denmark) Samsung Bioepis (Incheon, Republic of Korea)
	Renflexis	2017 (US)	Remicade	Biogen (Hillerod, Denmark) Samsung Bioepis
	lxifi	2017 (US)	Remicade	Pfizer
	Zessly	2018 (EU)	Remicade	Boehringer Ingelheim (Biberach an der Riss, Germany)
Adalimumab-based	Amgevita (EU) Amjevita (US)	2017 (EU) 2016 (US)	Humira	Amgen (Thousand Oaks, CA, USA)
	Solymbic	2017 (EU)	Humira	Amgen
	Cyltezo	2017 (EU & US)	Humira	Boehringer Ingelheim (Fremont, CA, USA)
	Halimatoz	2018 (EU)	Humira	Cook Pharmica (Bloomington IN, USA) Sandoz (Langkampfen, Austria)
	Hefiya	2018 (EU)	Humira	Cook Pharmica (Bloomington IN, USA) Sandoz (Langkampfen, Austria)
	Hyrimoz	2018 (EU)	Humira	Cook Pharmica (Bloomington IN, USA) Sandoz (Langkampfen, Austria)
	Imraldi	2017 (EU)	Humira	Biogen (Research Triangle Park, NC, USA) Biogen (Hillerød, Denmark)

Product type	Biosimilar (trade name)	Year (and region) approved	Reference product	Drug (active ingredient) manufacturer
Rituximab-based	Blitzima	2017 (EU)	MabThera	Celltrion
	Truxima	2017 (EU)	MabThera	Celltrion
	Ritemvia	2017 (EU)	MabThera	Celltrion
	Rituzena	2017 (EU)	MabThera	Celltrion
	Rixathon	2017 (EU)	MabThera	Sandoz (Langkampfen, Austria)
	Riximyo	2017 (EU)	MabThera	Sandoz (Langkampfen, Austria)
Trastuzumab-based	Ontruzant	2017 (EU)	Herceptin	Biogen (Hillerød, Denmark)
	Ogivri	2017 (US)	Herceptin	Mylan
	Herzuma	2018 (EU)	Herceptin	Celltrion
	Kanjinti	2018 (EU)	Herceptin	Patheon Biologics (Groningen, the Netherlands)
	Trazimera	2018 (EU)	Herceptin	Boehringer Ingelheim (Biberach an der Riss, Germany)
Bevacizumab-based	Mvasi	2018 (EU) 2017 (US)	Avastin	Amgen
Etanercept-based	Benepali	2016 (EU)	Enbrel	Biogen (Hillerød, Denmark)
	Erelzi	2017 (EU)	Enbrel	Sandoz (Novartis) (Langkampfen, Austria) (EU)
		2016 (US)		Novartis Pharma (Stein, Switzerland) (US)
Teriparatide-based				
Teriparatide-based	Movymia	2017 (EU)	Forsteo	Richter-Helm BioLogics (Bovenau, Germany)
	Terrosa	2017 (EU)	Forsteo	Richter-Helm BioLogics

of the product's mode of action and safety profile. Fasenra, by contrast, is engineered such that its glycocomponent is afucosylated (like that of Gazyva/Gazyvaro (obinutuzumab), approved initially in 2013), which increases the antibody-dependent cell-mediated cytotoxicity activity important for its mode of action. The period also witnessed the approval of one Fab antibody fragment (Praxbind; idarucizumab), designed to bind and thus neutralize the anticoagulant drug dabigatran.

Although technically outside the timeframe of this survey, the approval of Cablivi (caplacizumab) in Europe at the end of August represents a major milestone in mAb therapeutics, as it is the first nanobody to gain regulatory approval. It is indicated to treat acquired thrombotic thrombocytopenic purpura, which is a rare, life-threatening, autoimmune blood clotting disorder. Cablivi is a humanized, 259 amino acid, 2.78 kDa bivalent nanobody produced in E. coli that binds to von Willebrand factor, a key protein in hemostasis. This in turn inhibits the interaction of von Willebrand factor with blood platelets, preventing platelet adhesion and hence the clotting characteristic of the condition.

Although often considered the poster child of biopharma, antibody-based products are just as susceptible to commercial influence and pharmacovigilance as any other therapeutic product. Three mAbs approved in the current survey period have been withdrawn within this period. European marketing authorizations for Unituxin (dinutuximab, approved for neuroblastoma) from United Therapeutics and nivolumab BMS (nivolumab, approved for non-small-cell lung cancer) from Bristol-Myers Squibb were withdrawn, due to drug supply difficulties in the case of Unituxin and for commercial reasons in the case of nivolumab BMS. Biogen and AbbVie's Zinbryta (daclizumab), which was approved in 2016 for multiple sclerosis, was withdrawn globally in 2018 after serious adverse events, such as liver damage and immune reactions, became apparent.

Recombinant enzymes and transgenic production

The survey period also witnessed the approval of nine recombinant enzymes for the treatment of various genetic conditions. From a technological perspective, Alexion Pharmaceuticals' Kanuma (sebelipase alfa; recombinant human lysosomal acid lipase) is interesting in that it is produced in the eggs of transgenic chickens, with enzyme purification directly from transgenic egg white. The transgenic chicken line was developed via injection of a retroviral vector carrying the human coding sequence into chick embryos.

However, transgenic-based platforms for biopharmaceutical production have failed to gain widespread use in the biopharmaceutical sector. Technical challenges arising from random integration of transgenes into host chromosomes and the difficulty of controlling transgene copy number in production animals has limited the appetite for commercial investment in transgenic animal platforms capable of generating economically viable levels of recombinant proteins. It will be interesting to follow whether recent developments in CRISPR-based gene editing, which overcome some of these technical difficulties⁷, change the industry outlook. Ovalbumin, for example, is expressed at two grams per hen egg, with one hen capable of laying more than 300 eggs a year. CRISPR-targeted insertion of a therapeutic-protein-encoding sequence into the ovalbumin gene could therefore afford high-level protein production⁸.

Nucleic acid-based approvals

Nucleic acid-based products (gene therapies, DNA or RNA vaccines, ASOs, small interfering RNAs (siRNA), aptamers and modified RNA molecules) have yet to exert a profound influence on the biopharma product landscape, although the period witnessed the approval of five such products (three ASOs and two gene therapies). This brings the total tally of approvals in this category to nine, although the gene therapy Glybera (alipogene tiparvovec) was withdrawn from the market last year.

Glybera was approved as a single-administration gene therapy for adults suffering from familial lipoprotein lipase deficiency with a treatment price tag on the order of \$1 million. The developer and manufacturer opted not to renew its European marketing authorization in 2017 due to lack of demand for the product. Luxturna (voretigene neparvovec-rzyl), approved last year in the United States, appears set to be almost as costly; the one-time treatment will cost \$850,000. Luxturna contains a live, nonreplicating adeno-associated virus serotype 2 genetically modified to express the human retinal pigment epithelium-specific 65-kDa (*RPE65*) gene. Delivered directly via

subretinal injection, it is indicated for patients with inherited retinal disease due to mutations in both copies of this gene. The headline costs of either of these products likely reflect the rarity of the target conditions and thus potential market size, as opposed to a fundamental cost basis for gene therapy products per se. The third gene therapy approval, Imlygic (talimogene laherparepvec), for example, is projected to cost an average of \$65,000 per patient. Indicated for the treatment of melanoma recurrent after initial surgery, Imlygic is a live, attenuated herpes simplex virus type 1 carrying the human GM-CSF coding sequence. Viral replication subsequent to injection directly into the tumor is believed to trigger cell lysis, and it is believed that the release of tumor-derived antigens along with the GM-CSF may also promote an antitumor effect.

Three approved ASO products hold orphan status for the treatment of rare conditions with limited therapeutic options. It is notable that one of these ASO products, Ionis Pharmaceuticals' Spinraza (nusinersen) for spinal muscular atrophy, was the main source of sales growth for Biogen in 2017, generating \$188 million in sales in the first quarter of 2018. Spinraza targets splicing defects that lead to this disorder, and rare conditions arising due to mRNA mis-splicing are likely to be an increasing area of focus for this modality.

In terms of downregulation of misregulated mRNA expression, ASOs now have to compete with siRNAs. Although technically outside the timeframe of this current survey, the recent approval of Alnylam's Onpattro (patisiran) represents the most notable recent approval of an oligonucleotide-based therapeutic. Approved in both US and EU in August 2018, Onpattro is the first RNAibased gene expression silencing product to gain approval in either region.

Traditional biotech product approvals

The current survey period also witnessed the approval of 46 traditional biotech products classified as new by regulatory authorities in terms of active substance—just one more than recorded in our previous survey. Traditional products refer to those produced naturally or via nonrecombinant means in or by a biological source.

The profile of approvals (**Supplementary Table 1**) by and large mirrors product types approved in previous surveys and include a range of blood-derived products (for example, plasma-purified human albumin, clotting factors and immunoglobulins), as well as traditional (nonrecombinant) vaccines and nonengineered cells.

Box 2 Analytical approaches to validating biosimilar mAb quality

Biosimilar guidelines require the generation of comparative data between a proposed new biosimilar product and the reference product to which it claims similarity, at the levels of both the active substance and finished product. The marketing application, relative to a standard product application, must contain a full quality module, incorporating comparative quality analysis, as well as reduced comparative clinical and nonclinical data modules. Comparative quality studies largely rely on analytical techniques and instrumentation, now capable of fully characterizing biopharmaceuticals as large and complex as mAbs, with mass spectrometry (MS)-based techniques coming to the fore. Any comparative differences identified (for example, differences in glycocomposition) are then considered in terms of effect on biosimilarity, with further investigation via biological assay or preclinical or clinical evaluation, as appropriate.

An analysis of the comparative quality information presented in the European public assessment reports of approved biosimilar mAbs provide insight into the broad range of state-of-the-art analytical techniques used in practice (similar techniques are used as appropriate in the context of other protein-based biosimilars). The commonly applied analytical approaches discernible in these documents include the following:

- Determination of intact molecular mass by electrospray MS. Other size analysis modalities cited included size exclusion high performance liquid chromatography (SE-HPLC) and capillary electrophoresis in the presence of sodium dodecyl sulfate.
- Primary structural analysis by methods including classic C- and N-terminal sequencing (partial sequence determination), with full sequence determination invariably relying on initial protein fragmentation, peptide mapping and MS techniques such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS or liquid chromatography/tandem MS (LC-MS/MS). This includes the detection of C-terminal lysine variability (common in IgGs, but without anticipated clinical impact as C-terminal lysines are rapidly removed in serum).
- Sulfhydryl analysis via ultraviolet (UV)/visible light spectrophotometry and SE-HPLC, with disulfide linkage assignment via LC-MS-based peptide mapping under reducing and nonreducing conditions.
- Higher order structural analysis: secondary structural analysis via far-UV circular dichroism spectroscopy and/or Fourier transform infrared spectroscopy; tertiary analysis via near-UV circular dichroism spectroscopy or intrinsic fluorescence spectroscopy; thermal stability of higher order structure via differential scanning calorimetry; X-ray crystallography of the Fc domain.
- Glycosylation analysis: composition or structural determination, including levels of fucosylation and terminal galactosylation (which can influence antibody effector functions), by exoglucanase digestion and hydrophobic interaction chromatography analysis, high-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD).
- Analysis of additional modifications (for example, site specific deamidation, oxidation) by MS-based methods, peptide mapping with LC-MS).
- Charge heterogeneity profile by ion exchange-based HPLC, isoelectric focusing.
- Purity analysis: HPLC-based separation modalities based on size, charge and hydrophobicity, capillary gel electrophoresis, western blot analysis.

Engineered cell-based approvals

Traditional cell-based therapeutics containing cells extracted from human tissue or blood continue to come on the market. Examples include hematopoietic progenitor cells derived from cord blood, as well as autologous cultured chondrocytes used to treat cartilage defects (**Supplementary Table 1**).

A notable recent milestone in cell-based therapeutics is the approval of genetically engineered cell-based therapies, four of which have been approved since 2016: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Zalmoxis and Strimvelis. These products may be viewed as both cell and gene therapies, given that the cells carry a therapeutic gene into the patient's body. All four products have orphan status or target niche conditions and either are under additional monitoring or require further postauthorization safety studies. Three of the four (Kymriah, Yescarta and Strimvelis) use autologous cells, whereas the fourth (Zalmoxis) uses allogeneic cells as a starting point. One is a hematopoietic stem cell therapy (Strimvelis) and the other

Box 3 BiTE technology

Pioneered by Micromet, a biotechnology company acquired by Amgen, the first bispecific T-cell engager (BiTE) product, Blincyto (blinatumomab), gained approval in the United States and European Union for the treatment of B-cell precursor acute lymphoblastic leukemia during the current survey period. The BiTE platform consists of a bispecific antigen-binding antibody fragment, one arm of which is designed to bind the CD3 cell surface receptor complex, invariably found on cytotoxic T cells, while the other arm is designed to bind a surface tumor antigen associated with a target cancer cell type^{17,18}. The BiTE construct therefore acts as a bridge, bringing cytotoxic T cells into close proximity to the target cancer cells and triggering lysis of the latter by the former.

The Blincyto construct consists of two single-chain variable fragments (scFv domains) joined by a short, flexible linker sequence consisting of glycine and serine residues. The 55 kDa, 504 amino acid construct includes a C-terminal hexahistidine sequence, which facilitates purification using zinc-immobilized metal affinity chromatography. One scFv domain targets the T-cell CD3 receptor, while the other binds the pan-B-cell antigen CD19, facilitating T-cell-mediated lysis of B cells. Because of its relatively low molecular mass, the construct has a short serum half-life (2–3 h). This requires continuous infusion over a four-week period, representing a limitation in terms of patient convenience. Approaches to the development of next-generation constructs with extended serum half-lives include fusion to human albumin and Fc-based constructs, with an aim of facilitating a once-weekly dosage schedule.

The Amgen pipeline contains several more BiTE constructs undergoing phase 1 clinical trials for the treatment of various cancers, including multiple myeloma and acute myeloid leukemia. BiTE constructs targeting solid tumors have thus far yielded limited success. Limitations may include the degree of tumor penetration (by the construct and T cells), as well as the relatively broad expression of target antigen, which may limit dose escalation.

three are T-cell therapies. In all cases, genetic modification is undertaken *ex vivo* using a viral vector to achieve transduction, followed by infusion of the genetically modified cells into the patient.

Two of the products (Kymriah and Yescarta) fall into the new wave of cellular immunotherapies for oncology. They are notable in that they are the first chimeric antigen receptor (CAR)-T cell-based products9,10 to gain regulatory approval, effectively validating this technology from a regulatory standpoint. In addition to US approval in 2017, both gained marketing authorization in Europe in August 2018. In the case of both approved products, the CAR-T cells target the CD19 antigen, found on the surface of B lymphocytes, facilitating efficient T-cell-mediated destruction of B cells-thus their indication for the treatment of B-cellbased cancers, against which they have shown striking clinical results.

Future directions

Although published estimates vary somewhat, some 40% of the 6,000 or more products currently in clinical development globally are biopharmaceuticals. This suggests that the substantial increase in the proportion of approved pharmaceutical products that are biopharmaceuticals seen in this survey period is not a blip, but will be sustained into the future. The profile of products in advanced-stage clinical trials suggests that biopharmaceutical approvals over the next few years will continue to be predominantly protein-based (rather than nucleic acid- or cell-based), that they will be produced largely using conventional mammalian cell expression systems, that mAbbased products will continue to dominate the approvals, that a steady stream of biosimilars will continue to gain approval (particularly in indications with large, lucrative markets), and that cancer will remain the primary target indication.

Fifty-four genuinely new mAbs in late-stage clinical trials are under regulatory review in the United States and European Union¹¹, framing nearer-term putative approvals in these regions. Of these, 28 (52%) target cancer, 7 for liquid malignancies and 21 for solid tumors. Most are fully human or humanized IgGs, along with a smaller number (5) of antibody fragment (Fab or single-chain variable fragment (scFv)) products. Of the 28 anticancer products, 9 are conjugated to an effector molecule (radiolabel, chemical or toxin).

The antibody market, although highly successful, is also becoming very crowded. In some cases, multiple mAbs target the same therapeutic target (for example, CD20, TNF and vascular endothelial growth factor) and have overlapping indications. The mainstreaming of biosimilar mAbs and, potentially, the development of competing product types, such as CAR-T cell immunotherapies, further increases the competitive pressure and incentive to innovate. Not surprisingly, a greater diversity of modalities and targets is seen further back in the developmental pipeline, reflected in various antibody formats engineered to enhance functionality in some way, the pursuit of novel disease targets and the assessment of mAbs in combination with a second therapeutic agent.

Indeed, such competitive pressures have driven, and continue to drive, innovation among categories other than mAbs. For example, incentive to innovate is illustrated by the recent approval of several clotting factors engineered to increase serum half-life and an increasing number of trials assessing both previously approved and experimental biopharmaceuticals in combination with other drugs to treat various cancers.

Biosimilars will continue to feature with increasing prominence in the global biopharmaceutical landscape, but their greatest impact will continue to be in regions outside the more developed markets, such as the United States and European Union. Thus far, an estimated 260 biosimilar products have been approved in at least one global market—of which only a relatively small minority (52) have been approved in the European Union and/or the US. That being said, many of the additional products approved would likely find it challenging to meet EU and US regulatory expectations in the context of biosimilarity.

Globally, some 188 biosimilars are in development, 61 of which are in phase 3 trials¹². Specifically within Europe and the United States there are an estimated 50 biosimilars in development (https://www2.deloitte.com/ content/dam/Deloitte/us/Documents/lifesciences-health-care/us-lshc-biosimilarswhitepaper-final.pdf). Despite recent headline approvals, penetration in the US market in particular is likely to occur relatively slowly, underscored by regulatory and legal uncertainties, complex pricing and contracting mechanisms and, of course, patient and clinician acceptance. Overall, however, biosimilar market growth is anticipated to be strong, with market reports (e.g., https://www.marketsandmarkets.com/Market-Reports/biosimilars-40. html) typically forecasting a \$23 billion global market value within the next five to six years, up substantially from an estimated 2017 value of the order of \$4.5 billion.

The predominance of protein-based approved biopharmaceuticals is likely to remain an industry reality for the foreseeable future. Nucleic acid-based products have yet

to make a substantial and sustained impact on the list of biopharmaceutical products that are registered in Europe and the United States. A study¹³ from the Journal of Gene Medicine estimates that 2,597 gene therapy-based clinical trials have been approved globally since 1989. Despite this large body of data, gene-therapybased approvals in Europe and the United States remain in the single digits. Advances in adenoassociated virus (AAV) and lentiviral gene therapy modalities (particularly in ex vivo cellular therapy contexts)-together with increasing interest in CRISPR endonuclease-based gene editing, with several companies now poised to take such approaches into human testing-are likely to provide further impetus to the development of nucleic acid-based treatments.

The rapid advances and clinical adoption of T-cell-based adoptive therapies (including CAR-T cells) is a particularly notable development in the period of this study. The success of this cellular gene therapy is built on the exceptional responses obtained in some trials for some cancers, particularly liquid malignancies. However, scientific, technological and manufacturing hurdles may all complicate its more widespread adoption, certainly in the nearer term^{14–16}.

Overall, the past four and a half years have witnessed continued and accelerated growth in the biopharma sector. Antibodies continue to reign supreme and look to dominate for several years to come. Elsewhere, two developments in biopharmaceutical products have been particularly notable over the past five years. First, the massive proliferative capacity of cellular therapy has been effectively harnessed in the form of immunotherapy for late-stage cancers. It is this ability to identify, expand, attack and destroy malignant cells that has made CAR-T cell therapies so successful and overshadowed the longer term goal of cellular therapy: regeneration. Regenerative cell therapy was for many years seen as the main opportunity for modalities based on living cells and, in particular, stem cells; that is no longer the case. Second, increasing evidence of safety and growing familiarity of physicians and insurers with biosimilars means the economic advantages of these products are no longer being ignored. It seems likely that the rapid growth of biosimilar products will continue over the years to come.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper (doi:10.1038/nbt.4305).

- 1. Walsh, G. Biopharmaceutical benchmarks 2014. *Nat. Biotechnol.* **32**, 992–1000 (2014).
- Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).
- Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006).
- La Merie Business Intelligence. http://www.lamerie.com (2018).
- Biosimilars in the EU report: information guide for health professionals. https://www.ema.europa.eu/ documents/leaflet/biosimilars-eu-information-guidehealthcare-professionals_en.pdf (2017).

- The impact of biosimilar competition on price, volume and market share, June 2016. http://ec.europa.eu/ growth/content/impact-biosimilar-competition-pricevolume-and-market-share-updated-version-2016-0_en (2016).
- Bertolini, L.R. *et al.* The transgenic animal platform for biopharmaceutical production. *Transgenic Res.* 25, 329–343 (2016).
- Park, T.S. *et al.* Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. *FASEB J.* 29, 2386–2396 (2015).
- Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. *Curr. Pharm. Biotechnol.* 19, 5–18 (2018).
- June, C.H., O'Connor, R.S., Kawalekar, O.U., Ghassemi, S. & Milone, M.C. CAR T cell immunotherapy for human cancer. *Science* 359, 1361–1365 (2018).
- 11. Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. *MAbs* **10**, 183–203 (2018).
- FirstWord. Charting the Global Biosimilar Pipeline (FirstWord Publishing, 2018).
- Ginn, S.L., Amaya, A.K., Alexander, I.E., Edelstein, M. & Abedi, M.R. Gene therapy clinical trials worldwide to 2017: an update. *J. Gene Med.* 20, e3015 (2018).
- Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. *Drug Discov. Today* 23 1175– 1182 (2018).
- Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. *Nat. Biomed. Eng.* 2, 377–391 (2018).
- 16. Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. *Hum. Gene Ther.* 29, 559–568 (2018).
- Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. *Immunol. Rev.* 270, 193–208 (2016).
- Trivedi, A. *et al.* Clinical pharmacology and translational aspects of bispecific antibodies. *Clin. Transl. Sci.* 10, 147–162 (2017).

BIOPHARMACEUTICAL • nature Benchmarks biotechnology

Biopharmaceuticals are defined here as recombinant proteins, including recombinant antibody-based products, and nucleic acidbased and genetically engineered cell-based products. They are listed consecutively from most recent approval in each class, with registrations since 2014 in bold and withdrawals in red. Eight categories are shown: recombinant clotting factors; recombinant thrombolytics, anticoagulants and other blood-related products; recombinant hormones; recombinant growth factors; recombinant interferons, interleukins and tumor necrosis factor; recombinant vaccines; monoclonal antibody-based products; and other recombinant products. Where more than one drug in the same category was approved in a single year, they are listed alphabetically by trade name. Several products have been approved for multiple indications, but only the first indication for which it was approved is listed here. Some product entries describe the product as being the same as another listed product. In such instances differences invariably exist in terms of approved indication range or the company holding the marketing authorizations, usually as a result of commercial agreements.

Table 1 Biopharmaceuticals approved in the United States and European Union through end of July 2018

interfactor interpresentation in Basel any sector interpresentation in Basel basel in the product in	III, produced in CHO cells ihuma (simoctocog alfa), rh B-domain-deleted factor VIII, pro- uced in HEK cells. Same product as Nuwiq (see below) olias (octocog alfa), rh coagulation factor VIII, produced in BHK	& Kankakee, IL, USA)		2016 (US)
	uced in HEK cells. Same product as Nuwiq (see below) olias (octocog alfa), rh coagulation factor VIII, produced in BHK	•		2017 (EU)
Knothy ConstructionPays Parma (Ministrand and particle sequences of the sequen		•	Hemophilia A	2016 (EU)
endig workering and an end of	ovaltry (octocog alfa), rh coagulation factor VIII, produced BHK cells using the same expression construct as Bayer's	Bayer HealthCare (Whippany,	Hemophilia A	2016 (EU & US)
backed net Recalls. Same product at Whene (as alway)OSACall ACU J CatabaraContactureCall ACU J CatabaraContacture<			von Willebrand disease	2015 (US)
product of PNC only product of PNC on PC of P		USA)	Hemophilia A	
Ender and Park Proceedings of the Park Proceeding of the Park Procee	roduced in BHK cells	Baxter Healthcare (Westlake Village, CA, USA)	development of autoantibodies against factor VIII	2014 (US)
tar eccentral in Section protein in U.S. in capacitation fraction and the protein and the prot	stended half-life PEGylated form of full-length r factor VIII prod-		неторпіна А	2015 (05)
hendlight flandstrandter vill ander hild hand, beild, and service de	or recombinant, Fc fusion protein) in US: rh coagulation factor III–Fc fusion protein comprising B-domain-deleted human factor III covalently linked to the Fc domain of a human IgG, produced	(Stockholm) Biogen Idec (Cambridge, MA,	Hemophilia A	
dared in DO cells Arake forticing alls, in factor VIII, produced in DH oells Back Healmane (Vierna A, Berngchila A, 2003 (20) Back forticing alls, in factor VIII, produced in DH oells Back Healmane (Vierna A, Berngchila A, 2003 (20) Bernetics Installate (anthempshile factor), in factor VIII, produced in DH oells Back (Learnades), Market (Standard), Market S, Berning (Nieg Phass, Phass, Phase), Berning (Nieg Phass, Phass, Phase), Berning (Nieg Phass, Phass), Berning (Nieg Phass, Phase), Berning (Nieg Phass), Berning (Nieg P	ovoEight (turoctocog alfa), rh factor VIII analog that, when acti- ated, is structurally comparable to endogenous human factor	Denmark, & Plainsboro, NJ,	Hemophilia A	2013 (EU & US)
International operation Destrict Unspace 2003 (US) Refrect introcessog affa), fractor VII, produced in Hild Bayer (Berlin) Hempshila A 2000 (US) Refrect introcessog affa), fractor VII, produced in Mater VII, produced in CHO calls Proce Nyterin (Sacada Ch, USA) Hempshila A 2000 (US) Refrect introcessog affa), fractor VII, produced in CHO calls Berker, CA, USA) Hempshila A 1999 (US) Rescher, CA, USA) Berker, CA, USA Hempshila A 1999 (US) Rescher, Canada Charmane, Mater Rescher, CA, USA Hempshila A 1999 (US) Rescher, Canada Charmane, Mater Rescher, CA, USA Hempshila A 1991 (US) Rescher, Canada Charmane, Mater Rescher, CA, USA Fer patients treated with reserves 2016 (UL) Rescher, Canada Charmane, Mater Rescher, CA, USA Rescher, CA, USA Fer patients treated with reserves Rescher, Canada Charmane, CA, USA Rescher, CA, USA Fer patients treated with reserves 2016 (UL) Rescher Canada Charma	uced in CHO cells			
colis Plazer/Wyeth Usindolch, UN Plazer/Wyeth Usindolch, UN Plazer/Wyeth Usindolch, UN dicted in CHO Cells Min, USA, dicted in CHO Cells Min, USA, dicted in CHO Cells Saye (Leventusen, German, J., dicted in CHO Cells Saye (Leventusen, German, J., Biose (Leventusen, German, J., Herrophilia A Dicted in CHO Cells Saye (Leventusen, German, J., Biose (Leventusen, German, J., Herrophilia A Dicted in Chorner Saye (Leventusen, German, J., Recombinate (anthemophilic factor), In factor VIII, produced in CHO Avents Behring (Krig of Prasts, Prastice) Recombinate (anthemophilic factor), In factor VIII, produced in CHO cells San Francisco, CA, USA) Brance (herbane) San Francisco, CA, USA) Anternas (herbane) San Francisco, CA, USA) Recombinate, factor XD, produced in CHO cells and therbane, produced in CHO cells Branch (Leventusen, Cells and Cells and Cells and Cells and therbane, produced in CHO cells Branch (Leventusen, Cells and Cells and Cells and Cells and Cells and therbane, produced in CHO cells Br		Deerfield, IL, USA)		2003 (US)
Bisced in CHO cells Genetics institute (Cambridge, MU, USA) 1999 (EU) KAU, USA Bayer (Leverkuer, General), & Heinsphilia A 1999 (EU) Repeated in EHV cells Bayer (Leverkuer, General), & Heinsphilia A 1993 (US) Bischells (CA, USA) Bayer (Leverkuer, General), & Heinsphilia A 1993 (US) Bischells (CA, USA) Bayer (Leverkuer, General), & Heinsphilia A 1993 (US) Bischells (CA, USA) Baser Healthcare (Desrifue), Leverkuer, General), Leverkuer, General,	ells			
ducad in DHK cells. Sold as Hellands by Avertils Behring through a Behreine, CA, USA) 1993 (US)	uced in CHO cells	Genetics Institute (Cambridge, MA, USA)		1999 (EU)
eals PP, USA1 Batter Healtheare (Descripted, LL, Bernorphile A 1992 (US) CHC cells Batter Healtheare (Descripted, LL, Bernorphile A 1992 (US) CHC cells Cherophile Actors Portola Pharmaceuticals (South Interces Ac, produced in CHC cells and PCC	uced in BHK cells. Sold as Helixate by Aventis Behring through a cense agreement	a Berkeley, CA, USA)		1993 (US)
CHO cells USA), Genetics Institute Other Jood Lactors Andrexa (cosquilation factor Xa recombinant inactivated-shaw), r. Portola Pharmaceulicais (South tano regulation factor XD) in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD in US, Refrais (noncog beta pegol) in (Ur) to coguilation factor IXD results in patients (Ur) the Cells and PECylsted Grand Coguilation factor IXD results in patients (Ur) to Cells (UR) in (Ur) (Cells (UR) (UR) (UR) (UR) (UR) (UR) (UR) (UR)	ells	PA, USA)		
Andersa Cosputation factor Xa produced in CHO cells Partolia Pharmaceutical (South) For patients tracted with riversa of antic cogulation is needed due to antic cogulation factor XA produced in CHO cells and PCOylated 2017 (EU & US Rebinym (th cospulation factor XA produced in CHO cells and PCOylated Nevo Nordisk Hemophila B 2017 (EU & US Appoint Cell Terronanceg atta), th cospulation factor IX fused to any produced in CHO cells Biogen Idec (Maldenhead, UK, & Hemophila B 2016 (EU) Appoint Cell Terronanceg atta), th cospulation factor IX Appoint Cell State Costs CSL Behring Hemophila B 2016 (EU) Cell Alubrizeneous cog atta), th factor IX in sequation factor XI Appoint Cell State Costs Scale Behring 2018 (US) 2014 (UD) Risuble Inonanceg gamma), th factor IX, produced in CHO cells Basala Innorations (Vienna) appoint in US. Novchirteen in EU Catrificecog), th factor XIII Nov Nordisk Comporting Autoin Control on Intor beleding during support 2013 (US) Risk Cell Control Cells ZymoGenetics (Seattle) Some forms of hemophila Basala Innoactions (Vienna) appoint (Ethorations) 2008 (US) Risk Cell Control Cells Pixzer Nyeth Hemophila B 1999 (US) Basala Innoactions (Vienna) appoint (Ethoratingon appoint) Rect Meancega a	HO cells		Hemophilla A	1992 (US)
Rebinym (rh. coaguitation factor IX) in US, Retrika fromaceg beta peopl) in UL: the cognitation factor IX, produced in CHO cells and PEGylated New Nordisk Hemophila B 2017 (EU & US PEGylated Combining, moduled in FEX cells Biogen Idec (Maidenhead, UK, & Hemophila B 2016 (EU) Approlis (oftenonaceg alfa), th caguitation factor IX (recombinant)), th caguitation factor X, produced in CHO cells Biogen Idec (Maidenhead, UK, & Hemophila B 2016 (EU) N, produced in CHO cells Retro BioTherapeutics (Bernym, Paula Single Company), th factor IX, produced in CHO cells Sanata Innovations (Westake Vilage, CA, USA) Hemophila B 2013 (US) Risubis (nonaceg gamma), th factor IX, produced in CHO cells ZymoGenetics (Seattle) Control of minor biaeding during augery 2013 (US) Risubis (nonaceg galfa), th factor IXI, produced in CHO cells Prizer/Wyeth Hemophila B 1997 (EU & US Recoltrom (Inhombin), th factor IXI, produced in CHO cells Prizer/Wyeth Hemophila B 1997 (EU & US Recoltrom (Inhombin), th factor IXI, produced in CHO cells Prizer/Wyeth Hemophila B 1997 (EU & US Reter (sonaceg alfa), th factor IXI, produced in CHO cells Prizer/Wyeth Hemophila B 1997 (EU & US Reter (sonaceg alfa), th factor IXI, produced in CHO cells Rober/Hiogen Ingelheim, Germany) Mocardial Infarction			ban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled	2018 (US)
Alprohit (Retenenceq alls), th acceptiation factor X fused to a Carbonic of the Club acception of the	egol) in EU: rh coagulation factor IX, produced in CHO cells and		-	2017 (EU & US)
tein, produced in CHO cells instituti (coagulation factor X, freeombinant)), rh coagulation factor Apievo BioTherapeutics (Berrym, PA, USA) Baster Healthcare (Westlake Willage, CA, USA) Baster Healthcare (Westlake Willage, CA, USA) Baster Healthcare (Westlake Willage, CA, USA) Tetten in US, Novothiteen in EU (catridecog), rh factor XIII Assubunit, produced in S. cerevisiae Recottrom (Thomishi), rh factor II, produced in CHO cells Sater Healthcare (Westlake Willage, CA, USA) Seater Healthcare (Westlake Congenital factor XIII Assubunit 2013 (US) 2012 (EU) Surgery Novo Seven (eptacog affa, activated), rh factor VIIa, produced in BHK cells Benefix (nonacog affa), rh factor IX, produced in CHO cells Recombinant thrombolytics, anticoagulants and other blood-related products Tissue plasmingen activator Willdrawn 2000 TIMKase (tenecteplase), modified rh 1PA, produced in CHO cells Roche/Genericht (South San Freier (Nonacog affa), chractor IX, produced in CHO cells Roche/Genericht (South San Roche/Genericht (South San Roche/Gener	Iprolix (eftrenonacog alfa), rh coagulation factor IX fused to a		Hemophilia B	
Ky, produced in CHO cellsPÅ, USA)Hemophilia B2014 (EU)Risubis (nonacog gamma), rh factor IX, produced in CHO cellsBarter Healthcare (Westlake Barter Healthcare (Westlake Asubunit, produced in S. cerevisiaeCongenital factor XIII A-subunit deficiency2013 (US)Tretten in US, NovoRhirteen in EU (catridecog), rh factor XIIINovo Nordisk deficiencyCompenital factor XII A-subunit deficiency2013 (US)NovoSeven (eptacog affa, activated), rh factor VIIa, produced in CHO cellsZymoGenetics (Seattle)Control of minor bieeding during surgery2008 (US)NovoSeven (eptacog affa, activated), rh factor VIIa, produced in CHO cellsNovo NordiskSome forms of hemophilia1996 (EU) 1999 (US)Benefa's (nonacog affa), rh tactor IX, produced in CHO cellsPrizer/WyethHemophilia B1997 (EU & US)Benefa's (nonacog affa), rh tactor IX, produced in CHO cellsBoehringer ringelheim (Ingelheim, Germany)Myocardial infarction2001 (EU) Withdrawn 200TINKase (tenecteplase), modified rh IPA, produced in CHO cellsBoehringer ringelheim (Ingelheim, Germany)Myocardial infarction1996 (EU) Withdrawn 200TINKase (tenecteplase), rtPA, produced in CHO cellsRoche/Genentech (South San Moracrial infarction1996 (EU) Withdrawn 200Rabis (reteplase), rtPA (see Ecokinase above)Cheis USA (Cary, NC, USA) Activase (rateplase), rtPA (see Ecokinase above)Cheis USA (Cary, NC, USA) Activase (rateplase), rtPA (see Ecokinase above)Cheis USA (Cary, NC, USA) Activase (rateplase), rtPA (see Ecokinase above)Cheis USA (Cary, NC, USA) Acter myocardial infarction1996 (EU) <td>lelvion (albutrepenonacog alfa), rh factor IX-albumin fusion pro-</td> <td></td> <td>Hemophilia B</td> <td>2016 (EU & US)</td>	lelvion (albutrepenonacog alfa), rh factor IX-albumin fusion pro-		Hemophilia B	2016 (EU & US)
Bater Healthcare (Westlake2013 (US)Tretten in US, Novothirten in EU (catrideog), rh factor XIIINovo NordiskCongenital factor XII A-subunit, 2013 (US)Recentrom (finombin), nh factor III, produced in CHO cellsZymoGenetics (Seattle)Control of minor bleeding during surgery2008 (US)Novo Seven (eptacog alfa, activated), rh factor VIIa, produced inNovo NordiskSome forms of hemophilia1996 (EU)BHK cellsBenefix (nonacog alfa), rh factor IX, produced in CHO cellsPfizer/WyethHemophilia B1997 (EU & USBeendhinant thrombolytics, anticoagulants and other blood-related productsTrace plasminogen activator2001 (EU)Tissue plasminogen activatorRoche/Genentech (South San Francisco, CA, USA)Myocardial infarction2001 (EU)Withdrawa 200Withdrawa 200Withdrawa 200(US)TNKase (tenecteplase), modified rh tPA, produced in CHO cellsRoche/Genentech (South San Francisco, CA, USA)Myocardial infarction1996 (EU)Roche/Welwyn Garden City, UK)Acute myocardial infarction1996 (EU)Withdrawa 200Rolls (reteplase), r tPA (see Ecokinase above)Cheis USA (Cary, NC, USA)Acute myocardial infarction1996 (EU)Rolls (reteplase), r tPA (see Ecokinase above)Cheis USA (Cary, NC, USA)Acute myocardial infarction1996 (EU)Rolls (reteplase), r tPA (see Ecokinase above)Cheis USA (Cary, NC, USA)Acute myocardial infarction1997 (EU)Rolls (reteplase), r tPA (see Ecokinase above)Cheis USA (Cary, NC, USA)Acute myocardial infarction1997 (EU)Roll (reteplase), r tP			Hemophilia B	2015 (US)
A-subunit, produced in S. cerevisiaedeficiency2012 (EU)Recothrom (thrombin), th factor IIa, produced in CHO cellsZymoGenetics (Seattle)Control of minor bleeding during2008 (US)NovoSeven (eptacog alfa, activated), th factor VIIa, produced inNovo NordiskSome forms of hemophilia1996 (EU)BHK CellsBenefix (nonacog alfa), th factor IX, produced in CHO cellsPfizer/WyethHemophilia B1997 (EU & USRecombinant thrombolytics, anticoagulants and other blood-related productsTissue plasminogen activator2001 (EU)Wetalyse (tenecteplase), modified rh tPA, produced in CHO cellsBoehringer Ingelheim (Ingelheim, Germany)Myocardial infarction2000 (US)Trakses (tenecteplase), nodified rh tPA, produced in CHO cellsRoche/Genentach (South San Francisco, CA, USA)Myocardial infarction1996 (EU)Retives (reteplase), rt PA, produced in <i>EScherichia coli</i> , differsRoche/Welwyn Garden City, UK)Acute myocardial infarction1996 (EU)Retivase (reteplase), rt PA (see Ecokinase above)Actasi Group PTC (Hafmariforut, cleand), RocheAcute myocardial infarction1996 (EU)Retivase (ateplase), rt PA (see Ecokinase above)Chiesi USA (Cary, NC, USA)Acute myocardial infarction1997 (EU)Retivadan (kepirudin), r hirudin, produced in S. cerevisiaeCelgene Europe (Windsor, UK) Bayer HealthCareAnticoagulation therapy for hepa- rin-associated thrombocytopeni1997 (EU)Revase (desirudin), r hirudin, produced in S. cerevisiaeCaryon Pharmaceuticals (London)Symptomatic vitreomacular adhe- sion, vitreomacular adhe- Netharands)2014 (Baxter Healthcare (Westlake Village, CA, USA)		2013 (US)
surgery surgery NovoSeven (eptacog alfa, activated), rh factor VIIa, produced in Novo Nordisk Some forms of hemophilia 1996 (EU) Benefix (conacog alfa), rh factor IX, produced in CHO cells Prizer/Wyeth Hemophilia B 1997 (EU & US Recombinant thrombolytics, anticoagulants and other blood-related products Tissue plasminger activator 2001 (EU) Metalyse (tenecteplase), modified rh 1PA, produced in CHO cells Boehringer Ingelheim, Germany) Myocardial infarction 2000 (US) Trancisco, CA, USA) Roche/Genentech (South San Francisco, CA, USA) Myocardial infarction 1996 (EU) Withdrawn 200 Roche/Genentech (South San Francisco, CA, USA) Acute myocardial infarction 1996 (EU) Replayse (reteplase), rotpA, produced in CHO cells Roche/Welwyn Garden City, UK) Acute myocardial infarction 1996 (EU) Rapilysin (reteplase), rtPA, produced in CHO cells Roche/Genentech Acute myocardial infarction 1996 (EU) Retivase (ateplase), rt PA (see Ecokinase above) Chiesi USA (Car, NC, USA) Acute myocardial infarction 1997 (EU) Retivase (ateplase), rt PA (see Ecokinase above) Chiesi USA (Car, NC, USA) Acute myocardial infarction 1997 (EU)	-subunit, produced in S. cerevisiae		deficiency	2012 (EU)
Benefix (nonaccg alfa), rh factor IX, produced in CHO cells Pfizer/Wyeth Hemophilia B 1997 (EU & US Recombinant thrombolytics, anticoagulants and other blood-related products Tissue plasminogen activator 1997 (EU & US Metalyse (tenecteplase), modified rh tPA, produced in CHO cells Boehringer Ingelheim, Germany) Myocardial infarction 2000 (US) TNKase (tenecteplase), modified rh tPA, produced in CHO cells Roche/Genentech (South San Francisco, CA, USA) Myocardial infarction 1996 (EU) Ceckinase (reteplase), rtPA, produced in <i>Escherichia coli;</i> differs Roche/Genentech (South San Francisco, CA, USA) Acute myocardial infarction 1996 (EU) Rapilysin (reteplase), rtPA, produced in CHO cells Roche/Genentech Acute myocardial infarction 1996 (EU) Retavase (reteplase), rtPA (see Ecokinase above) Cheisi USA (Cary, NC, USA) Acute myocardial infarction 1996 (EU) Hirudin Refludan (lepirudin), r hirudin, produced in <i>S. cerevisiae</i> Celgene Europe (Windsor, UK) Acute myocardial infarction 1997 (EU) Bayer HealthCare Inassociated thrombocytopenia 1997 (EU) 1997 (EU) Withdrawn 200 Caryon Pharmaceuticals Prevention of venous thrombosis 1997 (EU) Bayer HealthCare Symptomatic vitreomacular taction 2013 (EU)			surgery	
Recombinant thrombolytics, anticoagulants and other blood-related products Tissue plasminogen activator Metalyse (tenecteplase), modified rh tPA, produced in CHO cells Roche/Genentech (South San Francisco, CA, USA) TNKase (tenecteplase), modified rh tPA, produced in CHO cells Roche/Genentech (South San Francisco, CA, USA) Trancisco, CA, USA) Trancisco, CA, USA Cerokinase (reteplase), rtPA, produced in <i>Escherichia coli</i> , differs Roche (Welwyn Garden City, UK) Acute myocardial infarction 1996 (EU) Withdrawn 200 Acute myocardial infarction 1997 (EU) Hirudin Refludan (lepirudin), r hirudin, produced in <i>S. cerevisiae</i> Celgene Europe (Windsor, UK) Refludan (lepirudin), r hirudin, produced in <i>S. cerevisiae</i> Canyon Pharmaceuticals (London) Cher Ruconest (conestat alfa), rh C1 esterase inhibitor, produced in the milk of transgenic rabbits Activas (altenjasnin), r hurucated form of human plasmin, produced In <i>Pichia pastoris</i> Acute (Luis, France), refVO Biologics (Francingham, MA, USA) Acute angioedema 2009 (US) Acuter your and the fransgenic goats Acuter your and the fransgenic goats Acuter of the angenic france of the angenic goats Acuter (ceallantide), plasma kallikrein inhibitor, produced in <i>R</i> Dyax (Cambridge, MA, USA) Acute angioedema 2009 (US) Cohe Chereitistic (Cambridge, MA, USA) Acute angioedema 2009 (US) Cohe Chiesi USA (Camb		Pfizer/Wyeth	Hemophilia B	1999 (US) 1997 (EU & US)
Metalyse (tenecteplase), modified rh tPA, produced in CHO cells Boehringer Ingelheim (Ingelheim, Germany) Myocardial infarction 2001 (EU) Withdrawn 200 TNKase (tenecteplase), modified rh tPA, produced in CHO cells Roche/Genentech (South San Francisco, CA, USA) Myocardial infarction 2000 (US) Ecokinase (reteplase), rt PA, produced in <i>Escherichia coli</i> , differs from human tPS domain shawe been deleted Roche/Genentech (South San Francisco, CA, USA) Acute myocardial infarction 1996 (EU) Rapilysin (reteplase), rt PA (see Ecokinase above) Actavis Group PTC (Hafnarfjordur, Iceland), Roche Acute myocardial infarction 1996 (EU) Retavase (reteplase), rt PA (see Ecokinase above) Chiesi USA (Cary, NC, USA) Acute myocardial infarction 1996 (EU) Mithdrawn 200 Chiesi USA (Cary, NC, USA) Acute myocardial infarction 1997 (EU) Retavase (reteplase), rt PA (see Ecokinase above) Celgene Europe (Windsor, UK) Bayer HealthCare Anticoagulation therapy for hepa- rin-associated thrombocytopenia 1997 (EU) Mihofaram 200 Caryon Pharmaceuticals (London) Prevention of venous thrombosis 1997 (EU) Mik of transgenic rabbits Santarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands) Symptomatic vitreomacular adhe- 2013 (EU) 2014 (US) 2010 (EU) O				
INKase (tenecteplase), modified rh tPA, produced in CHO cells Francisco, CA, USA) Myocardial infarction 2000 (US) Ecokinase (reteplase), r tPA, produced in <i>Escherichia coli</i> ; differs francisco, CA, USA) Roche (Welwyn Garden City, UK) Acute myocardial infarction 1996 (EU) Rapilysin (reteplase), r tPA (see Ecokinase above) Actavis Group PTC (Hafnarfjordur, Iceland), Roche Acute myocardial infarction 1996 (EU) Retavase (reteplase), r tPA (see Ecokinase above) Actavis Group PTC (Hafnarfjordur, Iceland), Roche Acute myocardial infarction 1996 (US) Retavase (reteplase), r tPA (see Ecokinase above) Chiesi USA (Cary, NC, USA) Acute myocardial infarction 1996 (US) Nativase (alteplase), r tPA, produced in CHO cells Roche/Genentech Acute myocardial infarction 1997 (EU) Revasc (desirudin), r hirudin, produced in <i>S. cerevisiae</i> Celgene Europe (Windsor, UK) Bayer HealthCare Anticoagulation therapy for hepa- rin-associated thrombocytopenia 1997 (EU) Other Undon) Prevention of venous thrombosis 1997 (EU) Nikh as at infanction, r hirudin, produced in milbitor, produced in the milk of transgenic rabbits Santarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands) Acute angioedema 2014 (US) Atryn (rh antithrombin), produced in milk of transgenic goats Laboratoire françia du frac- tionnement e		Boehringer Ingelheim	Myocardial infarction	2001 (EU)
Ecokinase (reteplase), r tPA, produced in <i>Escherichia coli</i> ; differs from human tPA in that 3 of its 5 domains have been deletedRoche (Welwyn Garden City, UK)Acute myocardial infarction1996 (EU) Withdrawn 200Rapilysin (reteplase), r tPA (see Ecokinase above)Actavis Group PTC (Hafnarfjordur, Iceland), RocheAcute myocardial infarction1996 (EU)Retavase (reteplase), r tPA (see Ecokinase above)Chiesi USA (Cary, NC, USA)Acute myocardial infarction1996 (US)Activase (alteplase), r tPA, produced in CHO cellsRoche/GenentechAcute myocardial infarction1996 (US)Activase (alteplase), r tPA, produced in S. cerevisiaeCelgene Europe (Windsor, UK) Bayer HealthCareAnticoagulation therapy for hepa- rin-associated thrombocytopenia1997 (EU) 1997 (EU)Revase (desirudin), r hirudin, produced in S. cerevisiaeCaryon Pharmaceuticals (London)Prevention of venous thrombosis1997 (EU) Withdrawn 201 (EU)OtherRuconest (conestat alfa), rh C1 esterase inhibitor, produced in the milk of transgenic rabbitsSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Acute angioedema2014 (US) 2010 (EU)Attryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les UII), France), next (SU Biologics (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Attryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les UIII), France), next (SU Biologics (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (E	NKase (tenecteplase), modified rh tPA, produced in CHO cells		Myocardial infarction	Withdrawn 2005 2000 (US)
Rapilysin (reteplase), r tPA (see Ecokinase above)Actavis Group PTC (Hafnarfjordur, Iceland), RocheActue myocardial infarction1996 (EU)Retavase (reteplase), r tPA (see Ecokinase above)Chiesi USA (Cary, NC, USA)Acute myocardial infarction1996 (US)Activase (alteplase), r tPA, produced in CHO cellsRoche/GenentechAcute myocardial infarction1996 (US)HirudinAcute myocardial infarction1987 (US)Refludan (lepirudin), r hirudin, produced in S. cerevisiaeCelgene Europe (Windsor, UK) Bayer HealthCareAnticoagulation therapy for hepa- in-associated thrombocytopenia1997 (EU) 1998 (US) Withdrawn 201 (EU)Revase (desirudin), r hirudin, produced in S. cerevisiaeCanyon Pharmaceuticals (London)Prevention of venous thrombosis 2010 (EU)1997 (EU) Withdrawn 201OtherSantarus (Raleigh, NC, USA)Acute angioedema2014 (US) 2010 (EU)Retra afa), rh C1 esterase inhibitor, produced in the in Pichia pastorisSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Symptomatic vitreomacular adhe- sion, vitreomacular traction2013 (EU) 2012 (US) 2012 (US)Attyrin (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), r EVO Biologics (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (EU) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in P. to asstorisDyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2002 (EU) 2006 (EU)Kigris (drotecogin alfa), rh a		, , ,	Acute myocardial infarction	
Retavase (reteplase), r tPA (see Ecokinase above)Chiesi USA (Cary, NC, USA)Acute myocardial infarction1996 (US)Activase (alteplase), rh tPA, produced in CHO cellsRoche/GenentechAcute myocardial infarction1987 (US)HirudinRefludan (lepirudin), r hirudin, produced in S. cerevisiaeCelgene Europe (Windsor, UK) Bayer HealthCareAnticoagulation therapy for hepa- rin-associated thrombocytopenia1997 (EU) 1998 (US) Withdrawn 201 (EU)Revasc (desirudin), r hirudin, produced in S. cerevisiaeCanyon Pharmaceuticals (London)Prevention of venous thrombosis1997 (EU) 1998 (US) Withdrawn 201 (EU)OtherRuconest (conestat alfa), rh C1 esterase inhibitor, produced in the milk of transgenic rabbitsSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Acute angioedema 2010 (EU) 2010 (EU)Jetrea (ocriplasmin), r truncated form of human plasmin, produced in <i>Pichia pastoris</i> ThromboGenics (Leuven, Belgium)Symptomatic vitreomacular adhe- sion, vitreomacular traction2013 (EU) 2012 (US)Attyn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), rEVO Biologies (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in <i>P. pastoris</i> Dyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2002 (EU) Withdrawn 201Kigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis2001 (US) 2002 (EU) Withd			Acute myocardial infarction	
Refludan (lepirudin), r hirudin, produced in S. cerevisiaeCelgene Europe (Windsor, UK) Bayer HealthCareAnticoagulation therapy for hepa- rin-associated thrombocytopenia1997 (EU) 1998 (US) Withdrawn 201 (EU)Revasc (desirudin), r hirudin, produced in S. cerevisiaeCanyon Pharmaceuticals (London)Prevention of venous thrombosis1997 (EU) 1998 (US) Withdrawn 201 (EU)OtherSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Acute angioedema2014 (US) 2010 (EU)OtherThromboGenics (Leuven, Belgium)Symptomatic vitreomacular adhe sion, vitreomacular adhe 2012 (US)2013 (EU) 2010 (EU)Atryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), rEVO Biologics (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in P. pastorisDyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Kigris (drotrecogin alfa), rh activated protein C, produced in A human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis2001 (US) 2002 (EU) Withdrawn 201		Chiesi USA (Cary, NC, USA)	*	
(EU)Revasc (desirudin), r hirudin, produced in S. cerevisiaeCanyon Pharmaceuticals (London)Prevention of venous thrombosis1997 (EU) Withdrawn 201OtherRuconest (conestat alfa), rh C1 esterase inhibitor, produced in the milk of transgenic rabbitsSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Acute angioedema2014 (US) 2010 (EU)Jetrea (ocriplasmin), r truncated form of human plasmin, produced in Pichia pastorisThromboGenics (Leuven, Belgium)Symptomatic vitreomacular adhe- 2012 (US)2013 (EU) 2012 (US)Atryn (rh antithrombin), produced in milk of transgenic goats tastorisLaboratorie français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), rEVO Biologics (Framingham, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in <i>P. pastoris</i> Dyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2002 (EU) Withdrawn 201Kigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis2001 (US) 2002 (EU) Withdrawn 201				
Ruconest (conestat alfa), rh C1 esterase inhibitor, produced in the milk of transgenic rabbitsSantarus (Raleigh, NC, USA) Pharming Group (Leiden, the Netherlands)Acute angioedema2014 (US) 2010 (EU)Jetrea (ocriplasmin), r truncated form of human plasmin, produced in Pichia pastorisThromboGenics (Leuven, Belgium)Symptomatic vitreomacular adhe- sion, vitreomacular traction2013 (EU) 2012 (US)Atryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), rEVO Biologics (Framingham, MA, USA)Hereditary antithrombin defi- ciency2009 (US) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in P. pastorisDyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Xigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis 2001 (US) 2002 (EU) Withdrawn 201	evasc (desirudin), r hirudin, produced in <i>S. cerevisiae</i>		Prevention of venous thrombosis	(EU)
Jetrea (ocriplasmin), r truncated form of human plasmin, produced in <i>Pichia pastoris</i> ThromboGenics (Leuven, Belgium)Symptomatic vitreomacular adhe- sion, vitreomacular traction2013 (EU) 2012 (US)Atryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France), rEVO Biologics (Framingham, MA, USA)Hereditary antithrombin defi- ciency2009 (US) 2006 (EU)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in <i>P. pastoris</i> Dyax (Cambridge, MA, USA)Hereditory angioedema2009 (US) 2006 (EU)Xigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis 2002 (EU) Withdrawn 201	uconest (conestat alfa), rh C1 esterase inhibitor, produced in the	Pharming Group (Leiden, the	Acute angioedema	
Atryn (rh antithrombin), produced in milk of transgenic goatsLaboratoire français du fractionnement et des biotechnologies (Les Ulis, France), rEVO Biologics (Framingham, MA, USA)Hereditary antithrombin deficiency2009 (US)Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in <i>P. pastoris</i> Dyax (Cambridge, MA, USA)Hereditory angioedema2009 (US)Xigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis2001 (US)2002 (EU)Withdrawn 201		d ThromboGenics (Leuven,		
Kalbitor (ecallantide), plasma kallikrein inhibitor, produced in P. pastorisDyax (Cambridge, MA, USA)Hereditory angioedema2009 (US)Xigris (drotrecogin alfa), rh activated protein C, produced in a human cell lineEli Lilly (Houten, the Netherlands)Severe sepsis2001 (US) 2002 (EU) Withdrawn 201		Laboratoire français du frac- tionnement et des biotechnolo- gies (Les Ulis, France),	Hereditary antithrombin defi-	2009 (US)
numan cell line Netherlands) 2002 (EU) Withdrawn 201				
(EU)		MA, USA)	Hereditory angioedema	2009 (US)

Admelog (insulin lispro injection), rapid-acting human insulin ana- Sanofi (Bridgewater, NJ, USA) Diabe log, produced in E. coli Diat Fiasp (insulin aspart injection), rapid-acting insulin analog, pro- Novo Nordisk duced in S. cerevisiae Insulin lispro Sanofi, produced in *E. coli*, biosimilar to Humalog Sanofi-Aventis (Paris) Diat Lusduna (insulin glargine), engineered insulin, produced in *E. coli*, Merck Sharp & Dohme Diabe biosimilar to Lantus (Hoddesdon, UK) Suliqua in EU, Soliqua in US (insulin glargine/lixisenatide), com- Sanofi-Aventis (Paris) Diat bination of long-acting insulin glargine, produced in E. coli, and a Sanofi (Bridgewater, NJ, USA) synthetically produced human GLP-1 analog Xultophy (insulin degludec/liraglutide), a combination of 2 previ- Novo Nordisk Diat ously approved products, Victoza and Tresiba Diabe Abasaglar (previously Abasria) in EU, Basaglar in US (insulin Eli Lilly (Indianapolis), glargine), produced in E. coli, biosimilar (in EU) to Lantus Boehringer Ingelheim (Ridgefield, CT, USA) Eli Lilly (Vienna) Ryzodeg 70/30 in US, Ryzodeg in EU (insulin degludec/insulin Novo Nordisk Dia aspart), combination of two engineered insulins, produced in S. cerevesiae Sanofi (Bridgewater, NJ, USA) Diabe Toujeo (insulin glargine), produced in E. coli Tresiba (insulin degludec), engineered long-acting human insulin Novo Nordisk Diat analog, produced in S. cerevisiae (see also Ryzodeg above) Afrezza (rh insulin), produced in E. coli MannKind (Danbury, CT, USA) Diab Novolog mix (insulin aspart mix), a 50:50 mixture of engineered Novo Nordisk Diat rh insulin, produced in S. cerevisiae in soluble and protamine suspension forms Insulin Human Winthrop (rh insulin), produced in E. coli Sanofi (Frankfurt) Exubera (inhalable rh insulin), produced in E. coli Pfizer (Sandwich, UK) Dia Levemir (insulin detemir), long-acting rh insulin, produced in S. Novo Nordisk Diab cerevisiae Apidra (insulin glulisine), rapid-acting insulin analog, produced Sanofi (Frankfurt) Dia in *E. coli* Actrapid, Velosulin, Monotard, Insulatard, Protaphane, Mixtard, Novo Nordisk Actraphane, Ultratard: rh insulin formulated as short-, intermed ate- or long-acting product, produced in S. cerevisiae Novolog (insulin aspart), short-acting rh insulin analog, produced Novo Nordisk Diat in S. cerevisiae Novolog mix 70/30 (contains insulin aspart, a short-acting rh insu- Novo Nordisk Diabe lin analog, in both soluble and crystalline form) (see also Novomix 30 below) Novomix 30 (contains a mixture of insulin aspart, a short-acting rh Novo Nordisk Diab insulin analog, in both soluble and crystalline form, produced in S. cerevisiae) Lantus (insulin glargine), long-acting rh insulin analog, produced Sanofi (Frankfurt) Diabe in *E. col*i Optisulin (insulin glargine), long-acting rh insulin analog, pro- Sanofi (Frankfurt) Diabe duced in E. coli (see also Lantus above) NovoRapid (insulin aspart), rh insulin analog), produced in S. Novo Nordisk Diab cerevisiae Liprolog (insulin lispro), insulin analog, produced in E. coli Eli Lilly (Houten, the Dia Insuman (rh insulin), produced in E. coli Sanofi (Frankfurt) Diabe Diabe Eli Lilly (Houten, the Humalog (insulin lispro), insulin analog, produced in E. coli Netherlands) Novolin (rh insulin), produced in S. cerevisiae Novo Nordisk Dia Humulin (rh insulin), produced in E. coli Eli Lilly (Indianapolis) Diat Human growth hormone Somatropin Biopartners (somatropin), r hGH, produced in Biopartners (Reutlingen, S. cerevisiae Germany) Accretropin (somatropin), r hGH, produced in E. coli **Emergent Biosolutions** Grov (Rockville, MD, USA) assoc Cangene (Winnipeg, MB, in ch Canada) Valtropin (somatropin), r hGH, produced in S. cerevisiae, biosimi- Biopartners lar to Humatrope LG Life Sciences (Reutlingen, ban Germany) Omnitrope (somatropin), r hGH, produced in *E. coli*, biosimilar (in Sandoz (Kundl, Austria) Cert Novartis (Princeton, NJ, USA) bance EU) to Genotropin Somavert (pegvisomant), PEGylated r hGH analog (antagonist), Pfizer (Brussels & New York) produced in *E. coli* Nektar Therapeutics (San Acror Francisco) Nutropin AQ (somatropin), r hGH, produced in *E. coli*, different Ipsen Pharma (Boulogne-Gro formulation of Nutropin (see below) Billancourt, France) Serostim (somatropin), r hGH, produced in mouse C127 cells EMD Serono (Geneva) AIDS Saizen (somatropin), r hGH, produced in mouse C127 cells EMD Serono (Rockland, MA, hGH Genotropin (somatropin), r hGH, produced in *E. coli* Pfizer (New York) hGH Norditropin (somatropin), r hGH, produced in E. coli Novo Nordisk Grow to inac sec Tev-Tropin, Bio-tropin (somatropin), r hGH, produced in *E. coli* Teva Pharmaceuticals (North hGH Wales, PA, USA) Nutropin (somatropin), r hGH, produced in E. coli Roche/Genentech hG⊢ Humatrope (somatropin), r hGH, produced in E. coli Eli Lilly (Indianapolis) hGH Protropin (somatrem), r hGH differing from hGH by an extra Genentech hGł N-terminal methionine, produced in E. coli Follicle-stimulating hormone Rekovelle (follitropin delta), rh FSH, produced in PER.C6 cells Ferring Pharmaceuticals Anov (Copenhagen) Bemfola (follitropin alfa), rh FSH, produced in CHO cells, biosimi- Finox Biotech (Burgdorf, Anov lar to Gonal F Switzerland) Ovaleap (follitropin alfa), rh FSH, produced in CHO cells, biosimi- Teva Pharma (Utrect, the Infer lar to Gonal F Netherlands) Elonva (corifollitropin alfa), a modified rh FSH in which the Merck Sharp & Dohme Con C-terminal peptide of the β-subunit of human chorionic gonadotropin is fused to the FSH β -chain, produced in CHO cells Fertavid (follitropin beta), rh FSH, produced in CHO cells. Active Merck Sharp & Dohme Infe substance same as that in Puregon (see below) Pergoveris (follitropin alfa/lutropin alfa) combination product Merck Serono (London) Stim containing rh FSH and rh luteinizing hormone, both produced in opme CHO cells defi Follistim (follitropin beta), rh FSH, produced in CHO cells Merck (Whitehouse Station, NJ, Infert USA) Puregon (follitropin beta), rh FSH, produced in CHO cells Merck Sharp & Dohme (Haarlem, Anovu the Netherlands) Gonal F (follitropin alfa), rh FSH, produced in CHO cells Merck Serono EMD Serono (Rockland, MD, USA)

Company (location)

Table 1 Continued

Product

Myalepta in EU, Myalept in US (metreleptin), rh leptin analog, produced in <i>E. coli</i>	Aegerion Pharmaceuticals (Amsterdam & Cambridge, MA, USA)	Some
Ozempic (semaglutide), human GLP-1 receptor agonist, produced in yeast and covalently modified by attachment of a C18 fatty acid	Novo Nordisk	Diabe
Movymia (teriparatide), rh parathyroid hormone fragment, pro- duced in <i>E. coli</i> , biosimilar to Fortseo. Same product as Terrosa (see below)	STADA Arzneimittel (Bad Vilbel, Germany)	Osteo
Natpar (parathyroid hormone), rh parathyroid hormone, full length, produced in <i>E. coli</i> . Same product as Preotact (see below).	Shire Pharmaceuticals Ireland (Dublin)	Нурор
Terrosa (teriparatide), rh parathyroid hormone fragment, produced in <i>E. coli</i> , biosimilar to Fortseo. Same product as Movymia (see	Gedeon Richter (Budapest)	Osteop

Natpara (parathyroid hormone), rh parathyroid hormone, produced Shire-NPS Pharmaceuticals

above)

(Lexington, MA, USA)

P. pastoris, biosimilar to Lantus in *E. coli*

NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 12 DECEMBER 2018

		Table 1 Continued				Table 1 Continued
 Therapeutic indication	Date approved	Product	Company (location)	Therapeutic indication	Date approved	Product
Diabetes mellitus Diabetes mellitus	2017 (US) 2017 (US)	Saxenda (liraglutide), human GLP-1 analog, produced in <i>S. cere- visiae</i> and covalently modified by palmitic acid. Active substance same as that in Victoza (see below)	Novo Nordisk	Obesity	2015 (EU)	Rebetron (ribavirin/interferon alfa-2b), produced in <i>E. coli</i> Infergen (interferon alficon-1), r IFN-α, synthetic type I, produced in <i>E. coli</i>
Diabetes mellitus	2017 (EU)	Eperzan in EU, Tanzeum in US (albiglutide), GLP-1 receptor ago- nist: two tandem copies of modified human GLP-1 fused to human albumin, produced in <i>S. cerevisiae</i>	GSK (Carrigaline, Ireland, & Research Triangle Park, NC, USA)	Diabetes mellitus type 2	2014 (EU & US)	Roferon A (interferon alfa-2a), produced in <i>E. coli</i>
Diabetes mellitus	2017 (EU) 2017 (US, tentative)	Trulicity (dulaglutide), fusion protein consisting of a GLP-1 analog linked to a human IgG Fc domain, produced in a mammalian cell	Eli Lilly (Utrecht, the Netherlands, & Indianapolis)	Diabetes mellitus type 2	2014 (EU & US)	
Diabetes mellitus type 2	2017 (EU) 2016 (US)	line Gattex in US, Revestive in EU (teduglutide), rh GLP-2 analog, produced in <i>E. coli</i>	NPS Pharma (Dublin)	Short bowel syndrome	2012 (EU & US)	Interferon- β and interferon- γ Plegridy (peginterferon beta-1a), rh PEGylated IFN- β -1a, produced in CHO cells
Diabetes mellitus type 2	2016 (US) 2014 (EU)	Victoza (liraglutide), GLP-1 analog with attached fatty acid, pro- duced in <i>S. cerevisiae</i>	Novo Nordisk	Diabetes mellitus type 2	2010 (US) 2009 (EU)	Extavia (interferon beta-1b), rh IFN β -1b, produced in <i>E. coli</i>
Diabetes mellitus	2015 (US) 2014 (EU)	Preotact, rh parathyroid hormone, produced in E. coli	NPS Pharma	Osteoporosis	2006 (EU) Withdrawn 2014	
Diskates mellitus ture 1 and 2		Fortical, r salmon calcitonin, produced in <i>E. coli</i>	Upsher-Smith Laboratories (Minneapolis) Unigene Laboratories (Fairfield,	Postmenopausal osteoporosis	2005 (US)	Rebif (interferon beta-1a), rh IFN-β-1a, produced in CHO cells Avonex (interferon beta-1a), rh IFN-β-1a, produced in CHO cells
Diabetes mellitus type 1 and 2	2015 (US) 2013 (EU)	Luveris (lutropin alfa), rh luteinizing hormone, produced in	NJ, USA) EMD Serono (Rockland, MA,	Some forms of infertility	2004 (US)	Betaferon (interferon beta-1b), r IFN-β-1b differing from native
Diabetes mellitus Diabetes mellitus type 1 and 2	2015 (US) 2015 (US) 2013 (EU)	CHO cells Forsteo in EU, Forteo in US (teriparatide), r shortened human	USA) Merck Europe (Amsterdam) Eli Lilly (Houten, the	Established osteoporosis in some	2000 (EU) 2003 (EU)	protein by C17S, produced in <i>E. coli</i> Betaseron (interferon beta- β -1b), differing from human protein by C17S, produced in <i>E. coli</i>
Diabetes mellitus	2014 (US)	parathyroid hormone, produced in <i>E. coli</i> Natrecor (nesiritide), rh natriuretic peptide, produced in <i>E. coli</i>	Netherlands) Johnson & Johnson/Scios	postmenopausal women Acutely decompensated conges-	2002 (US) 2001 (US)	Actimmune (interferon gamma-1b), produced in <i>E. coli</i>
Diabetes mellitus	2008 (US)	Ovitrelle in EU, Ovidrel in US (choriogonadotropin alfa) rh chori-	(Titusville, NJ, USA) Merck Serono	tive heart failure Selected assisted reproductive	2001 (EU)	Others
Diabetes mellitus	2007 (EU) Withdrawn 2018	onic gonadotropin, produced in CHO cells Thyrogen (thyrotropin alfa), rh thyroid-stimulating hormone, pro- duced in CHO cells	Sanofi Genzyme (Cambridge, MA. USA)	techniques Thyroid cancer (detection and treatment)	2000 (US) 1998 (US) 2000 (EU)	Kineret (anakinra), rh IL-1 receptor antagonist, produced in <i>E. coli</i> Beromun (tasonermin), rh TNF-α, produced in <i>E. coli</i>
Diabetes mellitus	2006 (EU & US) Withdrawn 2008	Forcaltonin, r salmon calcitonin, produced in <i>E. coli</i>	Unigene UK (Bushey Heath, UK)	treatment) Paget disease	2000 (EU) 1999 (EU) Withdrawn 2008	Neumega (oprelvekin), r IL-11 lacking N-terminal proline of native
Diabetes mellitus	(EU) 2005 (US) 2004 (EU)	Glucagen, rh glucagon, produced in <i>S. cerevisiae</i>	Novo Nordisk	Hypoglycemia	1998 (US)	molecule, produced in <i>E. coli</i> Proleukin (aldesleukin) r IL-2, differs from native molecule in
Diabetes mellitus	2004 (EU) 2004 (EU & US)	Glucagon (glucagon, recombinant), rh glucagon, produced in E. coli	Eli Lilly (Indianapolis)	Hypoglycemia	1998 (US)	absence of N-terminal alanine and presence of C125S substitu- tion, produced in <i>E. coli</i>
Diabetes mellitus	2002 (EU) Monotard and	Recombinant growth factors <i>Erythropoietin</i>				Recombinant vaccines Hepatitis B
	Ultratard with- drawn 2006	Retacrit (epoetin zeta in EU, epoetin alfa-epbx in US), rh EPO, produced in CHO cells, biosimilar to Eprex and Erypo	Hospira (Royal Learnington Spa, UK)	Anemia	2018 (US) 2007 (EU)	HEPLISAV-B (hepatitis B vaccine (recombinant) adjuvanted), HBsAg, produced in <i>Hansenula polymorpha</i> yeast
Diskatas as liitus	Velosulin with- drawn 2009	Biopoin (epoetin theta), rh EPO, produced in CHO cells	Pfizer (Lake Forest, IL, USA) Teva (Ulm, Germany)	Anemia	2009 (EU)	Hexacima, also sold as Hexyon, multi-component vaccine contain-
Diabetes mellitus	2001 (US) 2001 (US)	Eporatio (epoetin theta), rh EPO, produced in CHO cells Abseamed (epoietin alfa), produced in CHO cells, biosimilar to	Teva (UIm, Germany) Medice Arzneimittel Pütter	Anemia Anemia associated with chronic	2009 (EU) 2007 (EU)	ing r HBsAg, produced in <i>H. polymorpha</i> as one component Ambirix, combination vaccine containing r HBsAg, produced in
	2001(00)	Eprex/Erypo Binocrit (epoetin alfa), produced in CHO cells, biosimilar to Eprex/ Erypo	(Iserlon, Germany) Sandoz	renal failure Anemia associated with chronic renal failure	2007 (EU)	<i>S. cerevisiae</i> as one component Pediarix, combination vaccine containing r HBsAg, produced in
Diabetes mellitus	2000 (EU)	Epoetin alfa Hexal (epoietin alfa), produced in CHO cells, biosimi- lar to Eprex/Erypo	Hexal (Holzkirchen, Germany)	Anemia associated with chronic renal failure	2007 (EU)	S. cerevisiae as one component
Diabetes mellitus	2000 (EU & US)	Mircera (methoxy polyethylene glycol-epoetin beta) PEGylated rh EPO, produced in CHO cells	Roche (Welwyn Garden City, UK)		2007 (EU & US)	HBVAXPRO (r HBsAg), produced in <i>S. cerevisiae</i>
Diabetes mellitus	2000 (EU)	Silapo (epoetin zeta), produced in CHO cells, biosimilar to Eprex/ Erypo	STADA (Bad Vilbel, Germany) yes	Anemia associated with chronic renal failure	2007 (EU)	Twinrix, combination vaccine containing r HBsAg, produced in <i>S. cerevisiae</i> as one component
Diabetes mellitus	1999 (EU)	Dynepo (epoetin delta), rh EPO, produced in a human cell line	Shire Pharmaceuticals (Basingstoke, UK)	Anemia	2002 (EU) Withdrawn 2009	
Diabetes mellitus	1997 (EU) Withdrawn 2001	Aranesp (darbepoetin alfa), long-acting r EPO analog, produced in CHO cells (see Nespo below)	Amgen (Breda, the Netherlands)	Anemia	2001 (EU & US)	Infanrix-hexa, combination vaccine containing r HBsAg, produced in <i>S. cerevisiae</i> as one component
Diabetes mellitus Diabetes mellitus	1997 (EU) 1996 (EU & US)	Nespo (darbepoetin alfa), long-acting r EPO analog, produced in CHO cells (see Aranesp above)	Dompé Biotec (Milan)	Anemia	2001 (EU) Withdrawn 2008	Infanrix-penta, combination vaccine, containing r HBsAg, pro-
Diabetes mellitus	1991 (US)	Neorecormon (epoietin beta), rh EPO, produced in CHO cells Procrit (epoietin alfa), rh EPO, produced in a mammalian cell line	Roche Janssen Biotech (Horsham, PA,	Anemia Anemia	1997 (EU) 1990 (US)	duced in <i>S. cerevisiae</i> as one component
Diabetes mellitus	Withdrawn 2010 1982 (US)	Epogen (epoietin alfa), rh EPO, produced in CHO cells	USA) Amgen	Anemia	1989 (US)	Hepacare (r S, pre-S & pre-S2 HBsAg), produced in a murine cell line
 		Colony-stimulating factors Fulphila (pegfilgrastim-jmdb), PEGylated rh G-CSF, produced in	Mylan (Rockford, IL USA)	Neutropenia	2018 (US)	Hexavac, combination vaccine containing r HBsAg, produced in <i>S. cerevisiae</i> as one component
Growth failure, growth hormone deficiency Growth failure or short stature	2013 (EU) Withdrawn 2017 2008 (US)	<i>E. coli</i> , biosimilar to Neulasta Nivestym (filgrastim-aafi) in US, Nivestim (filgrastim) in EU: rh	Pfizer (Lake Forest, IL, USA)	Neutropenia	2018 (US)	Procomvax, combination vaccine containing r HBsAg as one com- ponent
associated with Turner syndrome in children	2008 (03)	G-CSF, produced in <i>E. coli</i> , biosimilar to Neupogen	Hospira (Royal Learnington Spa, UK)		2010 (EU)	Primavax, combination vaccine containing r HBsAg, produced in <i>S. cerevisiae</i> as one component
Certain forms of growth distur-	2007 (US)	Ristempa (pegfilgrastim), covalent conjugate of rh G-CSF, pro- duced in <i>E. coli</i> and conjugated to 20-kDa polyethylene glycol	Amgen (Breda, the Netherlands)	•	2015 (EU) Withdrawn 2017	Engerix B, r HBsAg, produced in <i>S. cerevisiae</i> Infanrix Hep B, combination vaccine containing r HBsAg, pro-
bance in children and adults	2006 (EU) Withdrawn 2012 (EU)	Zarxio in US, Zarzio in EU (filgrastim-sndz), rh G-CSF, produced in <i>E. coli</i> Accofil (filgrastim), G-CSF, produced in <i>E. coli</i> , biosimilar to	Sandoz (Princeton, NJ, USA, & Kundl, Austria) Accord Healthcare (Ahmedabad,	Neutropenia Neutropenia	2015 (US) 2009 (EU) 2014 (EU)	duced in <i>S. cerevisiae</i> as one component Comvax, combination vaccine containing HBsAg, produced in <i>S.</i>
Certain forms of growth distur- bance in children and adults	2006 (EU & US)	Neupogen. Same product as Grastofil (see below) Grastofil (filgrastim), rh G-CSF, produced in <i>E. coli</i> , biosimilar to	India) Apotex (Leiden, the Netherlands)		2014 (EU)	<i>cerevisiae</i> as one component Tritanrix-Hep B, combination vaccine containing r HBsAg, pro-
Acromegaly	2003 (US) 2002 (EU)	Neupogen. Same product as Accofil (see above) Lonquex (lipegfilgrastim), PEGylated rh G-CSF, produced in <i>E. coli</i>		Neutropenia	2013 (EU)	duced in <i>S. cerevisiae</i> as one component Recombivax, r HBsAg, produced in <i>S. cerevisiae</i>
Growth failure, Turner syndrome	2001 (EU) 1994 (US)	Granix (tbo-filgrastim), rh G-CSF, produced in E. coli. Same prod-	Netherlands) Teva Pharmaceuticals USA	Neutropenia	2012 (US)	Other
	Withdrawn 2008 (EU)	uct as Tevagrastim (see below)	(Frazer, PA, USA) Cephalon (Malvern, PA, USA)	Neutonenia	2000 (511)	Shingrix (zoster vaccine recombinant, adjuvanted), recombinant varicella zoster virus surface glycoprotein E antigen component,
AIDS-associated catabolism and wasting	1996 (US)	Filgrastim Hexal (filgrastim), produced in <i>E. coli</i> , biosimilar to Neupogen Biograstim (filgrastim), produced in <i>E. coli</i> , biosimilar to	Hexal ABZ-Pharma (UIm, Germany)	Neutropenia Neutropenia	2009 (EU)	produced in CHO cells Trumenba (meningococcal group B vaccine), two r <i>Neisseria men</i> -
hGH deficiency in children	1996 (US)	Neupogen Ratiograstim (filgrastim), produced in <i>E. coli</i> , biosimilar to	Ratiopharm (UIm, Germany)	Neutropenia	Withdrawn 2015 2008 (EU)	ingitides serogroup B proteins, independently expressed in <i>E. coli</i> Pandemic influenza vaccine H5N1, vaccine derived from engi-
hGH deficiency in children Growth failure in children due	1995 (US) 1995 (US)	Neupogen Tevagrastim (filgrastim), produced in <i>E. coli</i> , biosimilar to	Teva (Radebeul, Germany)	Neutropenia	2008 (EU)	neered viral strain containing gene segments from appropriate viral influenza strains, produced in embryonated eggs
to inadequate growth hormone secretion hGH deficiency in children	1995 (US)	Neupogen. Same product as Granix (see above) Filgrastim Ratiopharm (filgrastim), produced in <i>E. coli</i> , biosimilar	Ratiopharm	Neutropenia	2008 (EU) With drawn 2011	Bexsero (meningococcal group B vaccine), mixture of 3 <i>N. menin- gitidis</i> serogroup B proteins, produced in <i>E. coli</i>
hGH deficiency in children	1993 (US)	to Filgrastim Neulasta in EU and US, Neupopeg in EU (pegfilgrastim),	Amgen (Breda, the Netherlands)		Withdrawn 2011 2002 (EU & US)	Gardasil 9, mixture of the major capsid protein (L1) of 9 strains of HPV, each produced in <i>S. cerevisiae</i>
hGH deficiency in children	1987 (US) 1985 (US)	PEGylated rh G-CSF		penia	Neupopeg with- drawn 2008 (EU)	Mosquirix (<i>Plasmodium falciparum</i> and hepatitis B vaccine), virus- like particles comprising the RTS fusion protein of a portion of the
	Withdrawn 2004	Leukine (sargramostim), rh GM-CSF differing from the native pro- tein by an R23L substitution, produced in <i>E. coli</i>	Sanofi-aventis U.S. (Bridgewater, NJ, USA)	Autologous bone marrow trans- plantation	1991 (US) Withdrawn 2008	circumsporozoite protein from <i>P. falciparum</i> and the N- terminal end of HBsAg, coexpressed in <i>S. cerevisiae</i>
 Anovulation	2016 (EU)				and reformu- lated without EDTA 2008	Flublok, r hemagglutinin proteins from 3 influenza viruses, pro- duced in an insect cell line
Anovulation (women), failure of spermatogenesis (men)	2014 (EU)	Neupogen (filgrastim), rh G-CSF differing from native protein by an extra N-terminal methionine, produced in <i>E. coli</i>	Amgen (Thousand Oaks, CA, USA)	Chemotherapy-induced neutro- penia	1991 (US)	Provenge (sipuleucel-T), autologous peripheral blood mononuclear cells in combination with r prostatic acid phosphatase linked to GM-CSF, produced in an insect cell line
Infertility, subfertility	2013 (EU)	Other growth factors				Cervarix, r C-terminally truncated major capsid L1 proteins from
Controlled ovarian stimulation	2010 (EU)	Oxervate (cenegermin), rh nerve growth factor, produced in <i>E. coli</i> Increlex (mecaserim), rh IGF-1, produced in <i>E. coli</i>	Dompé Farmaceutici (Milan) Ipsen Pharma	Neurotophic keratitis Growth failure in children with IGF-1 deficiency or hGH gene	2017 (EU) 2007 (EU) 2005 (US)	HPV types 16 and 18, produced in a baculovirus-based expression system Gardasil in EU & US, Silgard in EU, r vaccine containing major
Infertility	2009 (EU)	iPlex (mecasermin rinfabate), a complex of rh IGF-1 and rh IGF	Insmed (Glen Allen, VA, USA)	deletion (long-term treatment) Growth failure in children with	2005 (US)	capsid proteins from four HPV types, produced in <i>S. cerevisiae</i>
Stimulation of follicular devel- opment in women with severe	2007 (EU)	binding protein-3, produced separately in <i>E. coli</i>		severe primary IGF-1 deficiency or hGH gene deletion (long-term	Withdrawn 2007 for IGF-1 defi-	Dukoral (Vibrio cholerae and r cholera toxin B subunit)
luteinizing hormone and FSH deficiency		Kepivance (palifermin), rh keratinocyte growth factor, produced in	Swedish Orphan Biovitrum	treatment Severe oral mucositis in selected	ciency 2005 (EU) 2004 (US)	Lymerix (r OspA), a lipoprotein found on the surface of <i>B. burgdor-feri</i> , produced in <i>E. coli</i>
Infertility	1997 (US)	E. coli		patients with hematologic cancers	2004 (0S) Withdrawn 2016 (EU)	Triacelluvax, combination vaccine containing r modified pertussis toxin as one component
Anovulation and superovulation	1996 (EU)	GEM 21S: Regranex (see below) and tricalcium phosphate; growth-factor-enhanced matrix	BioMimetic Pharmaceuticals (Franklin, TN, USA)	Periodonatally related defects	2005 (US)	Monoclonal antibody–based products Aimovig (erenumab-aooe in USA, erenumab in EU), human IgG2
Anovulation and superovulation	1997 (US) 1995 (EU)	Regranex (becaplermin), rh platelet-derived growth factor receptor- BB, produced in <i>S. cerevisiae</i>	Johnson & Johnson (Raritan, NJ, USA) Janssen-Cilag International (Beerse, Belgium)	Lower extremity diabetic neuro- pathic ulcers	1997 (US) 1999 (EU) Withdrawn 2012 (EU)	targeting the calcitonin gene-related peptide receptor, produced in CHO cells
Some forms of lipodystrophy	2018 (EU)	Recombinant interferons, interleukins and tumor necrosis factor	(200.50, Delgruill)			Crysvita (burosumab in EU, burosumab-twza in USA), human IgG1 antibody to soluble fibroblast growth factor-23, produced in CHO cells
Diabates mellitus trus 0	2014 (US)	Interferon-α PEG-Intron/Rebetol combo pack (peginterferon alfa-2b/ribavirin)	Schering Plough (Kenilworth,	Chronic hepatitis C	2008 (US)	Fasenra (benralizumab), humanized, afucosylated IgG1 targeting the α subunit of the human IL-5 receptor, produced in CHO cells
Diabetes mellitus type 2 Osteoporosis	2018 (EU) 2017 (US) 2017 (EU)	PEGylated rh IFN- α -2b, produced in <i>E. coli</i> , and ribavirin Pegasys (peginterferon alfa-2a), PEGylated IFN- α -2b, produced in <i>E. coli</i>	NJ, USA) Roche/Genentech (Welwyn Garden City, UK)	Hepatitis C	2002 (EU & US)	Halimatoz (adalimumab), anti-TNF IgG, produced in CHO cells, biosimilar to Humira. Same product as Hefiya and Hyrimoz (see
		in <i>E. coli</i> PEG-Intron (peginterferon alfa-2b), PEGylated IFN-α-2b, produced in <i>E. coli.</i>		Chronic hepatitis C	2001 (US) 2000 (EU)	biosimilar to Humira. Same product as Heriya and Hyrimoz (see below)
Hypoparathyroidism	2017 (EU)	Viraferon (interferon alfa-2b), produced in <i>E. coli</i>	Schering Plough (Brussels, Belgium)	Chronic hepatitis B, C	2000 (EU) Withdrawn 2008	Hefiya (adalimumab), anti-TNF IgG, produced in CHO cells, bio- similar to Humira. Same product as Halimatoz and Hyrimoz (see
Osteoporosis	2017 (EU)	ViraferonPeg (peginterferon alfa-2b), PEGylated IFN- α -2b, produced in <i>E. coli</i>	Merck Sharp & Dohme	Chronic hepatitis C	2000 (EU)	above and below) Hemlibra (emicizumab in EU, emicizumab-kxwh in US), human-
Hypocalcemia	2015 (US)	Intron A, Alfatronol (interferon alfa-2b), produced in E. coli	Merck Sharp & Dohme	Cancer, genital warts, hepatitis B and C, HPV	2000 (EU) 1986 (US)	ized, bispecific IgG4 capable of binding factor IXa and factor X, produced in CHO cells

	Company (location)	Therapeutic indication	Date approved
ed	Schering Plough Astellas Pharma Europe	Chronic hepatitis C Chronic hepatitis C	1999 (US) 1999 (EU)
cu	(Leiderdorp, the Netherlands) Kadmon Pharmaceuticals	Chrome nepatitis C	1999 (EU) 1997 (US) Withdrawn 2006
	(Warrendale, PA, USA)		(EU)
	Roche	Hairy cell leukemia	1986 (US) Withdrawn 2007
	Biogen Idec (Maidenhead, UK)	Multiple sclerosis	2014 (EU & US)
	Novartis Europharm (Camberley,	Multiple sclerosis	2009 (US)
	UK) Novartis Pharmaceuticals (East		2008 (EU)
	Hanover, NJ, USA) EMD Serono (London)	Relapsing/remitting multiple	2002 (US)
		sclerosis	1998 (EU)
5	Biogen Idec (Maidenhead, UK)	Relapsing multiple sclerosis	1997 (EU) 1996 (US)
	Bayer Pharma	Multiple sclerosis	1995 (EU)
by	Berlex Laboratories (Richmond,	Relapsing/remitting multiple sclerosis	1993 (US)
	CA, USA) Chiron (Emeryville, CA, USA)		
	Vidara Therapeutics (Dublin)	Chronic granulomatous disease	1990 (US)
coli	Swedish Orphan Biovitrum	Rheumatoid arthritis	2001 (US)
	Boehringer Ingelheim	Adjunct to surgery for subsequent	1999 (EU)
	(Ingelheim, Germany)	tumor removal to prevent or delay amputation	
ive	Pfizer (Philadelphia), Genetics Institute	Prevention of chemotherapy- induced thrombocytopenia	1997 (US)
	Prometheus Laboratories (San Diego)	Renal cell carcinoma	1992 (US)
	Diego)		
	Dynavax Technologies (Berkeley,	Prevention of infection caused by	2017 (US)
	CA, USA)	all known subtypes of hepatitis B virus	
in-	Sanofi Pasteur (Lyon, France)	Immunization against several	2013 (EU)
	GSK (Rixensart, Germany)	pathogens and toxins Immunization against hepatitis	2002 (EU)
	GSK	A and B Immunization of children against	2002 (US)
	GSN	various conditions inducing	2002 (03)
	Sanofi Pasteur	hepatitis B Immunization of children and	2001 (EU)
	GSK	adolescents against hepatitis B Immunization against hepatitis	2001 (US)
	Con	A and B	1997 (EU pedi- atric form)
			atric form) 1996 (EU adult form)
ed	GSK	Immunization against diphtheria,	2000 (EU)
		tetanus, pertussis, <i>Haemophilus influenzae</i> b, hepatitis B and	
	GSK	polio Immunization against diphtheria,	2000 (EU)
	dok	tetanus, pertussis, polio, and hepatitis B	Withdrawn 2013
ell	Evans Vaccines (Liverpool, UK)	Immunization against hepatitis B	2000 (EU)
S.	Sanofi Pasteur	Immunization against diphtheria,	Withdrawn 2002 2000 (EU)
0.		tetanus, pertussis, hepatitis B, polio and <i>H. influenzae</i> b	Withdrawn 2012
n-	Sanofi Pasteur	Immunization against <i>H. influen</i> -	1999 (EU)
		zae b and hepatitis B	Withdrawn 2009
า	Sanofi Pasteur	Immunization against diphtheria,	1998 (EU)
٦		tetanus and hepatitis B	Withdrawn 2000
l	Sanofi Pasteur GSK GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria,	Withdrawn 2000 1998 (US) 1997 (EU)
n	GSK GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005
1	GSK GSK Merck (Whitehouse Station, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US)
n :.	GSK GSK Merck (Whitehouse Station, NJ,	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU)
n :.	GSK GSK Merck (Whitehouse Station, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, Immunization against hepatitis B,	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU)
1	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014
n t	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU)
n t	GSK GSK Werck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US)
t.	GSK GSK Werck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU)
t	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US)
t t	GSK GSK Werck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles)	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU)
t t iral	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA,	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N.</i>	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2016 (EU)
t t iral	GSK GSK Werck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2016 (EU)
t iral	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA,	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV-	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2016 (EU) 2015 (US) 2013 (EU)
t irral of us-	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2015 (EU) 2015 (EU) 2015 (EU);
t irral of us-	GSK GSK Werck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (US) 2016 (EU) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU) 2014 (US)
t iral	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2015 (EU) 2015 (EU) 2015 (EU); approved for use
t in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) ClaxoSmithKline Biologicals (Rixensart, Belgium)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i>	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (EU) 2014 (US) 2015 (US) 2013 (EU) 2015 (EU); approved for use outside the EU 2013 (US)
t in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i>	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (US) 2016 (EU) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (EU) 2010 (US)
t in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) ClaxoSmithKline Biologicals (Rixensart, Belgium)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i>	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (US) 2017 (US) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (EU)
in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) ClaxoSmithKline Biologicals (Rixensart, Belgium)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Prevention of herpes zoster (shingles) Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i>	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (US) 2016 (EU) 2016 (EU) 2015 (EU) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (US)
in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Protein Sciences (Meriden, CT, USA) Dendreon (London) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) Withdrawn 2015 (EU) 2013 (EU) 2013 (US) Withdrawn 2015 (EU)
in- of us- he l	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Protein Sciences (Meriden, CT, USA) Dendreon (London) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B Vaccine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (EU) 2013 (US) Withdrawn 2015 (EU); 2019 (US)
in- of us- he l	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Protein Sciences (Meriden, CT, USA) Dendreon (London) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B decine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prevention of cervical cancer Vaccination against diseases caused by HPX	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2016 (EU) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) Withdrawn 2015 (EU) 2013 (US) Withdrawn 2015 (EU) 2013 (US)
t in- of us- he l	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) ClaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline Biologicals (Rixensart, Belgium) Cosh (Unitehouse Station, NJ, USA) Dendreon (London)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B decine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2013 (US) 2013 (US) 2013 (US) 2013 (US) 2013 (US) 2013 (US) 2010 (US) Withdrawn 2015 2009 (US) 2007 (EU) 2006 (EU & US)
t in- of us- he l ion	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GalaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Frotein Sciences (Meriden, CT, USA) Dendreon (London) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B deceine against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2015 (US) 2015 (US) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (US) Withdrawn 2015 2009 (US) 2009 (US) 2006 (EU & US) 2004 (EU) 1998 (US) Withdrawn 2005
t in- of us- he l ion	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Frotein Sciences (Meriden, CT, USA) Dendreon (London) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B decrime against <i>N. meningitides</i> serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by <i>V. cholerae</i> subunit O1 Immunization against Lyme	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (US) 2009 (US) 2009 (US) 2006 (EU & US) 2004 (EU) 1998 (US)
t in- of us- he l ion	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Frotein Sciences (Meriden, CT, USA) Dendreon (London) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B difuenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU) 2014 (US) 2015 (EU) 2013 (EU) 2013 (US) 2013 (US) 2013 (US) 2013 (EU) 2009 (US) 2007 (EU) 2009 (US) 2007 (EU) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002
t in- of us- he l ion	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) Frotein Sciences (Meriden, CT, USA) Dendreon (London) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against N. meningitides serogroup B Influenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit 01 Immunization against diseases caused by V. cholerae subunit 01	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (EU) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (US) 2009 (US) 2009 (US) 2006 (EU & US) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU)
t irral of us-	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B difuenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU) 2014 (US) 2015 (EU) 2013 (EU) 2013 (US) 2013 (US) 2013 (US) 2013 (EU) 2010 (US) Withdrawn 2015 (EU) 2009 (US) 2007 (EU) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002
t an- of iral in- of cof cof cof cof cof cof cof	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Merck (Stockholm) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B difuenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) 1996 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU) 2014 (US) 2015 (EU) 2013 (EU) 2013 (US) 2013 (US) 2013 (US) 2013 (EU) 2010 (US) Withdrawn 2015 (EU) 2009 (US) 2007 (EU) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002
t an- of iral in- of cof cof cof cof cof cof cof	GSK GSK GSK GSK GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against N. meningitides serogroup B Influenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by V. cholerae subunit O1 Immunization against diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (EU) 2017 (US) 2015 (US) 2015 (EU); 2015 (EU); 2015 (EU); 2013 (US) 2013 (US) 2013 (US) 2009 (US) 2009 (US) 2006 (EU & US) 2006 (EU & US) Withdrawn 2002 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002 1999 (EU) Withdrawn 2002 1993 (US) Withdrawn 2002 1993 (EU) Withdrawn 2002 1993 (EU) Withdrawn 2002
t in- of is cor- is cor- is cor- is	GSK GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) McdImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK Chiron (Siena, Italy) Amgen (Thousand Oaks, CA, USA) Novartis (East Hanover, NJ, USA) Novartis Europharm (Dublin)	tetanus and hepatitis B Immunization against hepatitis B Immunization against diphtheria, tetanus, pertussis and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against <i>N.</i> <i>meningitidis</i> serogroup B Active immunization against MPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit O1 Immunization against diseases caused by K. cholerae subunit O1 Immunization against diseases	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU); approved for use outside the EU 2013 (US) 2013 (US) 2010 (US) Withdrawn 2015 2009 (US) 2006 (EU & US) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002 1999 (EU)
t in- of is cor- is cor- is cor- is	GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical (Novato, CA, USA) AstraZeneca (Södartälje, Sweden, & Wilmington, DE, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B Immunization against hepatitis B, diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>V. cholerae</i> subunit O1 Immunization against disease caused by <i>V. cholerae</i> subunit O1 Immunization against disease caused by <i>V. cholerae</i> subunit O1 Immunization against disease caused by <i>V. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis	Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2015 (US) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2013 (EU) 2013 (US) 2013 (US) 2013 (EU) 2013 (EU) 2013 (EU) 2013 (EU) 2014 (US) 2015 (EU); approved for use outside the EU 2013 (EU) 2014 (US) 2009 (US) 2007 (EU) 2006 (EU & US) Withdrawn 2002 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002 2018 (EU & US) 2018 (EU & US) 2018 (EU) 2018 (EU)
t in- of is cor- is cor- is cor- is	GSK GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GSK Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK Chiron (London) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Margen (Thousand Oaks, CA, USA) Novartis (East Hanover, NJ, USA) Novartis (East Hanover, NJ, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against M. meningitidis serogroup B Active immunization against M. meningitidis serogroup B Active immunization against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diphtheria, tetanus and pertussis X-linked hypophosphatemia Asthma	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (US) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (EU) 2017 (US) 2016 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2013 (US) 2013 (US) 2013 (US) 2013 (EU) 2010 (US) Withdrawn 2015 (EU) 2009 (US) 2007 (EU) 2006 (EU & US) 2004 (EU) 1998 (US) Withdrawn 2002 1999 (EU) Withdrawn 2002 2018 (EU & US) 2018 (EU & US)
t in- of is cor- is cor- is cor- is	GSK GSK GSK GSK GSK GSK GSK GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research friangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Ketherlands GSK GlaxoSmithKline Biologicals (Rixensart, Belgium) Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK GSK GSK Chiron (Siena, Italy) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Novartis Europharm (Dublin) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical (Novato, CA, USA) AstraZeneca (Södartälje, Sweden, & Wilmington, DE, Sandoz	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against <i>N. meningitidis</i> serogroup B Active immunization against M. <i>meningitidis</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by HPX Immunization against diseases caused by V. cholerae subunit O1 Immunization against diphtheria, tetanus and pertussis Vacination against diphtheria, tetanus and pertussis Various inflammatory conditions mediated by TNF, including rheumatoid arthritis and plaque psoriasis	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (US) 2016 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2013 (EU) 2013 (EU) 2013 (US) 2013 (EU) 2010 (US) 2010 (US) 2006 (EU & US) 2006 (EU & US) 2006 (EU & US) 2006 (EU & US) 2018 (EU) 2018 (EU) 2018 (EU) 2018 (EU) 2018 (EU)
t in- of ion lor- is	GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Sanofi Pasteur Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical (Novato, CA, USA) AstraZeneca (Södartälje, Sweden, & Wilmington, DE, USA)	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against disease caused by <i>K. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis Immunization against diphtheria, tetanus and pertussis Various inflammatory conditions mediated by TNF, including rheumatoid arthritis and plaque psoriasis Various inflammatory conditions mediated by TNF, including	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2017 (US) 2017 (US) 2015 (EU) 2014 (US) 2015 (EU) 2015 (EU) 2014 (US) 2014 (US) 2014 (US) 2014 (US) 2015 (EU) 2014 (US) 2015 (EU) 2014 (US) 2014 (EU) 2014 (EU) 2014 (EU) 2014 (EU) 2015 (EU) 2014 (EU) 2014 (EU) 2015 (EU) 2014 (EU) 2014 (EU) 2015 (EU
and	GSK GSK GSK GSK GSK GSK GSK GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research friangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Netherlands Ketherlands GSK GlaxoSmithKline Biologicals (Rixensart, Belgium) Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK GSK GSK Chiron (Siena, Italy) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Novartis Europharm (Dublin) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical (Novato, CA, USA) AstraZeneca (Södartälje, Sweden, & Wilmington, DE, Sandoz	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against H. influenzae b and hepatitis B diphtheria, tetanus and pertussis Immunization against N. meningitidis serogroup B Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite Plasmodium falciparum Immunization against influenza Prostate cancer Vaccination against diseases caused by HPX Immunization against diseases caused by HPX Migraine Migraine Migraine Various inflammatory conditions mediated by TNF, including rheumatoid arthritis and plaque psoriasis Various inflammatory conditions	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2018 (EU) 2017 (EU) 2017 (EU) 2016 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2015 (EU) 2013 (EU) 2013 (EU) 2013 (US) 2013 (EU) 2010 (US) 2010 (US) 2006 (EU & US) 2006 (EU & US) 2007 (EU) 2006 (EU & US) 2006 (EU & US) 2018 (EU & US) 2018 (EU) 2018 (EU) 2018 (EU)
and	GSK GSK GSK GSK GSK GSK GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research Triangle Park, NC, USA) Pfizer (Philadelphia) McdImmune (Nijmegen, the Netherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, GSX GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Chiron (London) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical Novartis Europharm (Dublin) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical Sandoz Sandoz	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against N. meningitidis serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against diseases caused by <i>N. cholerae</i> subunit O1 Immunization against diseases caused by <i>N. cholerae</i> subunit O1 Immunization against diseases caused by <i>N. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis Immunization against diphtheria, tetanus and pertussis X-linked hypophosphatemia Asthma Various inflammatory conditions mediated by TNF, including rheumatoia HTMF, including rheumatoia HTMF, including polyarticular juvenile idiopathic	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2017 (US) 2017 (US) 2015 (EU) 2013 (US) 2013 (US) 2013 (US) 2010 (US) Withdrawn 2015 2009 (US) 2007 (EU) 2006 (EU & US) 2007 (EU) 2006 (EU & US) Withdrawn 2002 1998 (US) Withdrawn 2002 2018 (EU) 2018 (EU) 2018 (EU) 2018 (EU) 2018 (EU)
and and a second	GSK GaxoSmithKline Biologicals (Rixensart, Belgium) GlaxoSmithKline (Research friangle Park, NC, USA) Pfizer (Philadelphia) MedImmune (Nijmegen, the Metherlands Novartis (Cambridge, MA, USA, & Siena, Italy) MSD (Lyon, France) Merck (Whitehouse Station, NJ, USA) GlaxoSmithKline Biologicals (Rixensart, Belgium) GSK GSK Canofi Pasteur Merck (Whitehouse Station, NJ, USA) Dendreon (London) GSK Chiron (Siena, Italy) Marck (Whitehouse Station, NJ, USA) Valneva Sweden (Stockholm) GSK Chiron (Siena, Italy) Kyowa Kirin (Galashiels, UK) Ultragenyx Pharmaceutical (Novatis (Cadashiels, UK) Ultragenyx Pharmaceutical (Novatis (Cadashiels, UK) Ultragenyx Pharmaceutical Sandoz	tetanus and hepatitis B Immunization against hepatitis B Immunization of infants against <i>H. influenzae</i> b and hepatitis B diphtheria, tetanus and pertussis Immunization against hepatitis Serogroup B Influenza vaccine Active immunization against <i>N. meningitides</i> serogroup B Active immunization for those above 9 years of age against HPV- caused cancers and genital warts Vaccination against malaria caused by the parasite <i>Plasmodium falciparum</i> Immunization against influenza Prostate cancer Vaccination against diseases caused by <i>N. cholerae</i> subunit O1 Immunization against diseases caused by <i>N. cholerae</i> subunit O1 Immunization against disease caused by <i>N. cholerae</i> subunit O1 Immunization against diphtheria, tetanus and pertussis Immunization against diphtheria, tetanus and pertussis Various inflammatory conditions mediated by TNF, including pheumatoid arthritis and plaque psoriasis Various inflammatory conditions mediated by TNF, including polyarticular juvenile idiopathic arthritis and plaque psoriasis	 Withdrawn 2000 1998 (US) 1997 (EU) Withdrawn 2005 1996 (US) 1996 (EU) Withdrawn 2014 1986 (US) 2017 (US) 2017 (US) 2015 (EU) 2014 (US) 2015 (EU) 2015 (EU) 2014 (US) 2014 (US) 2014 (US) 2014 (US) 2015 (EU) 2014 (US) 2014 (EU) 2009 (US) 2007 (EU) Withdrawn 2002 1999 (EU) Withdrawn 2002 1999 (EU) Withdrawn 2002 2018 (EU & US) 2018 (EU) 2018 (EU) 2018 (EU) 2018 (EU)

InstructureInstructu	Table 1 Continued Product Herzuma (trastuzumab), r humanized IgG1 against HER2, pro-	Company (location) Celltrion Healthcare (Budapest)	Therapeutic indication Breast and gastric cancers	Date approved 2018 (EU)
Image:Answer:Amounts <t< td=""><td>duced in CHO cells, biosimilar to Herceptin Hyrimoz (adalimumab), anti-TNF IgG, produced in CHO cells, biosimilar to Humira. Same product as Halimatoz and Hefiya (see</td><td>•</td><td>Various inflammatory conditions mediated by TNF, including</td><td></td></t<>	duced in CHO cells, biosimilar to Herceptin Hyrimoz (adalimumab), anti-TNF IgG, produced in CHO cells, biosimilar to Humira. Same product as Halimatoz and Hefiya (see	•	Various inflammatory conditions mediated by TNF, including	
action of controlMarterCarter of controlControContro <td< td=""><td></td><td></td><td>•</td><td>2018 (US)</td></td<>			•	2018 (US)
generationcontrol <td>duced in CHO cells, biosimilar to Herceptin</td> <td>Netherlands)</td> <td>-</td> <td></td>	duced in CHO cells, biosimilar to Herceptin	Netherlands)	-	
abs/sParturePartureSouther settingSouther settingSouther settingConcentreCon	IgG antibody to human VEGF-A1, produced in CHO cells, biosimi-	Amgen (Thousand Oaks, CA,	Various cancers	
Interactional content in the probability of the proba	geting the CD33 surface antigen, consisting of a humanized IgG4 chemically conjugated to <i>N</i> -acetyl-γ-calicheamicin, produced in NSO mouse myeloma cells	Pfizer/Wyeth (Philadelphia)		2000 (US) Withdrawn 2010 (US) Reapproved 2017 (US) using modified dosage and regimen
orthoremetricensembleIndensity and the sectorConstruction <td>face antigen, produced in CHO cells</td> <td>Genentech (South San Francisco, CA, USA)</td> <td></td> <td>2017 (US)</td>	face antigen, produced in CHO cells	Genentech (South San Francisco, CA, USA)		2017 (US)
one of each of both isUnit of each o	cells, biosimilar to Herceptin		esophageal junction adenocar- cinoma	
cold, because interfact offerenceAdditional and a finite interface of a finite inter	domain, produced in NSO cells	USA) Theratechnologies (Montreal)	type 1 infection	
line of DL () motion of motio	cells, biosimilar to Remicade (infliximab) Amgevita (adalimumab), anti-TNF human IgG1, produced in CHO cells, biosimilar to Humira. Same product as Solymbic and		additional inflammatory diseases Rheumatoid arthritis and selected	
Initial control of the same of the sam	ligand-1 (PD-L1), produced in CHO cells	Pfizer (New York)	urothelial carcinoma	2017 (EU & US)
CDD2, produced in CHO calls, biosing try them in the proprious in the prop	sisting of a humanized IgG4 specific for human CD22, produced in CHO cells, covalently linked to the cytotoxic agent <i>N</i> -acetyl-γ- calicheamicin dimethylhydrazide	Pfizer/Wyeth (Philadelphia)		
ajoint numma TMP, produced in CPO clip, basining to this search of clip action basis, perform all indications ball indications basis, p	CD20, produced in CHO cells, biosimilar to MabThera Same product as Ritemvia, Truxima and Rituzena (see below)	(Budapest)	granulomatosis	
product a durbule size haloo Departer dignitures, hours ig 64 bub lish the L4 seeper is regenered privates in the CP of the CP of the CP of the Interaction of the CP of the C	against human TNF, produced in CHO cells, biosimilar to Humira Dinutuximab beta Apeiron (dinutuximab beta), chimeric IgG1	Germany) Boehringer Ingelheim (Ridgefield, CT, USA)	tions, including psoriasis, rheumatoid arthritis and Crohn's disease	
Interfact containable, human ig 12 blacking be stated of a point of a state of the calors interpret of the ca	product as Qarziba (see below) Dupixent (dupilumab), human IgG4 that binds the IL-4α receptor	Bridgewater, NJ, USA), Regeneron Pharmaceuticals	Atopic dermatitis	2017 (EU & US)
International information between the control of the control of the control information of the control of the contro	grammed cell death ligand-1 (PD-L1) with its receptor PD-1 and	AstraZeneca (Wilmington, DE,	Urothelial carcinoma	2017 (US)
List De Renicada Including Phenumbol and articlis, Service of in CPD cells, Service Articles Artic	Imraldi (adalimumab), produced in CHO cells, biosimilar to			2017 (EU)
discale in CHO cellsIndigenerity NU, USA), Regression Amazolita, Carrytow, NY, USA), Regression Amazolita, Carrytow, NY, USA, Distance, Statis, USA, Deckelmand, Junnan Lei Z, Statis, Carrytow, NY, USA, Distance, Carrytow, NY, USA, Restating Carrytow, NY, USA, Restation, NY, USA, <b< td=""><td></td><td>Pfizer (New York)</td><td>including rheumatoid arthritis,</td><td>2017 (US)</td></b<>		Pfizer (New York)	including rheumatoid arthritis,	2017 (US)
imma IL-17 recepter A, produced in CHO cells, biosimilar to Watent Pharmacuticals (Briggenster, NJ, USA)Breast and gastric cancers (A) (US)2017 (US)Optical functionab deta), produced in CHO cells, biosimilar to to Azarchio and dinutstrimab beta pervisus/ diruturimab beta EUSA and dinutstrimab beta feeropain and dinutstrimab feeropain and dinutstrimab feeropain and dinutstrimab feeropain and dinutstrimab feeropainCellstrima feeropain and feeropain and feeropain and dinutstrimab feeropain and dinutstrimab feeropain and feeropainCellstrima feeropain and feeropain and feeropain and feeropain and feeropainCellstrima feeropain and feeropainCellstrip and feeropain and feeropain and feeropain and feeropain and feeropain and feeropain and feeropainCellstrip and feeropain <br< td=""><td></td><td>Bridgewater, NJ, USA), Regeneron Pharmaceuticals</td><td>Rheumatoid arthritis</td><td></td></br<>		Bridgewater, NJ, USA), Regeneron Pharmaceuticals	Rheumatoid arthritis	
HenceginZurichOntruzant, porticular ICNC of It, biosimilar to HerceginSamurg Biopis UK (Brentford).Beast and gastric cancers of 2017 (EU)Ontruzant, and maturinas beta Apteriori, chimaric (EG) against catachy produced in CMC of It, biosimilar to Semurade Samurg Biopis UK (Brentford).Neuroblastoma2017 (EU)Refereix (infinitaba-bidd), chimaric (EG) Taba think TW- produced in CMC of It, biosimilar to Benciade. Same producet an produced in CMC of It, biosimilar to Benciade. Same producet an 		Denmark) Valeant Pharmaceuticals	Psoriasis	
Jourtha difuluinab beta perviously dirulturinab beta SpeinorUK)Reuroblastoma2017 (EU)and dirutturinab beta Apelerol, chimeric IgG1 againt carboly dired dialagengiole GD2, which is a neuroblastoma cells, produced in PCO cells, losinillar to Remicede. Same product as Fitzabi (cen below)Revic (Kenilweth, NJ, USA)Crohn's disease and various other 	Herceptin	& Zurich)	-	
Penders (Inflixinab-bible), chimeric [§1] Hat binds TNF-a, produced in (FAO cells, biosimilar to Manifera Same product as Bitzina, Rituzen and Tuxina (see above and below)Merck (Kenilwerth, NJ, USA)Control disease and sections.2017 (US)Rittua (Huismab), produced in CHO cells, biosimilar to MabThera. Same product as Bitzina, Rituzen and Tuxina (see above and below)Celltrion Healthcare Hungary Rittua (Hyphonia, CLL menotogini (Sister Same)Non-Hodgkin (hyphonia, graulio macroscipi (populations), molecule (CHO cells, biosimilar to MabThera. Same product as Bitzina, Rituzen and toxical in CHO cells, biosimilar to MabThera. Same product as Bitzina, Rituzen and toxical in CHO cells, biosimilar to MabThera. Same product as Riturno (the eabove)Celltrion Healthcare Hungary mon-Hodgkin (hyphonia, CLL, mon-Hodgkin (hyphonia, CLL, mon-Hodgkin (hyphonia, CLL, mon-Hodgkin (hyphonia, CLL, mon-Hodgkin (hyphonia), cllumeric [G1 againt cell surface antigen CD20, produced (ICHO cells, biosimilar to MabThera. Same product as Riturno (tells, biosimilar to MabThera. Same product as Riturno, tells, biosimilar to MabThera. Same product as Riturno (tells, biosimilar to MabThera. Same product as Riturno, tells, biosimilar to MabT	Qarziba (dinutuximab beta; previously dinutuximab beta EUSA and dinutuximab beta Apeiron), chimeric IgG1 against carbohy- drate disialoganglioside GD2, which is overexpressed by cells of neuroectodermal origin such as neuroblastoma cells, produced in	UK) EUSA Pharma (Hemel	-	
MabThera. Same product as Bitzima, Rituzena and Tuxima (see above and below)metasis with polyangilis, micro- scopic polyangilis, micro- 	produced in CHO cells, biosimilar to Remicade. Same product as Flixabi (see below)		inflammatory conditions	
duced in CHO cellsGenemechIarge B-cell lymphoma, CLUPittarean (orrowsky Turelia) (ritukinab), produced in CHO cellsCelltionNon-Hodgkin hymphoma, CLUPittarean (orrowsky Turelia) (ritukinab), chimeric IgG1 against cell surface antigenSandoznon-Hodgkin hymphoma, CLUCD20, produced in CHO cells, biosimilar to MalThera. Same product as Ritukino (see below)SandozVarious conditions including non- thou anticid arthritis, but excluding CLUSolymbic (cabiimumab), chimeric IgG1 against cell surface antigen CD20, produced in CHO cells, biosimilar to MalThera. Same product as Ritukino (see above)SandozVarious conditions including non- cell ingramatori distantistic, but excluding CLUSolymbic (cabiimumab), anti-TIF Fhuman IgG1 specific for pro- grammed dath ligand (PD-L1), engineerd to lack Fe glycosy) adio, noduced in CHO cellsRoche Registration (Grenzach- Wyhlen, Germany) Grancisco, CA, USA)Pioriasis2017 (EU & US 2016 (US)Turufar (truutab), human IgG1 that selectively binds bar subunit of L-23, produced in CHO cellsRoche Registration (Grenzach- Wyhlen, Germany) Grancisco, CA, USA)Selected cancers anatoin- mune Gorders2017 (EU & US 2016 (US)Turufar (truutab), chimeric IgG1 against cell surface antigen CD20, produced in CHO cellsMerck Marp & Dohm munet Cho Cells2017 (EU 2016 (US)Turufar (tabinamab-b, chimeric IgG1 against Cell surface antigen CD20, produced in CHO cellsReck Rarp & Dohm munet Cell calce cancers ana soli- munet Cell cell cell calce cancers ana soli- munet Cell cell cell calce cancers ana soli-<	MabThera. Same product as Blitzima, Rituzena and Truxima (see above and below)		matosis with polyangiitis, micro- scopic polyangiitis	
Tuxima (see above and below) Sandoz Various conditions including non-Hodgkin (mphona, CLL, relations (including non-Hodgkin (mphona, CLL, relations), chimeric (gG1 against cell surface antigen (CD20, produced in CHO cells, biosimilar to MabThera, Same product as Rutation (see above) Sandoz Various conditions including non-Hodgkin (mphona, CLL, relations), chimeric (gG1 against cell surface antigen (GE120, produced in CHO cells, biosimilar to MabThera, Same product as Rutation (see above) Sandoz Various conditions including non-Hodgkin (mphona, CLL, relations), thumanized (gG1 against cell surface antigen (GE120, produced in CHO cells, biosimilar to MabThera, Same product as Angevita (see above) Angen Europe Reche Registration (Genzach- Wirle, Genzach- Kirle, WirleHouxes Station, NJ, USA) 2017 (EU) 2017 (EU)	duced in CHO cells Rituzena (previously Tuxella) (rituximab), produced in CHO cells,	Genentech	large B-cell lymphoma, CLL Non-Hodgkin lymphoma, CLL,	
uct as Riximy (see below) rheumatol antirits Piximy (Hiximab), chimeric [G1 against cell surface antigen (220, produced in CH0 cells, biosimilar to MabThera. Same produced in CH0 cells, biosimilar to ManThera. Same produced in CH0 cells, biosimilar to Munta, same produced as Amgevita and Amjevita (see above) Angen Europe Reche Registration (Genzach White, Genzach) Differential carcinoma, non-small 2017 (EU) 2017 (EU) Selombic (adaInnumab), humanized IgG1 specific for pro- grammed dash lignal 1 (Pb.L1), engineered to lack Fe givcov)- ation, produced in CH0 cells Roche Registration (Genzach White, Genzach) Urothetial carcinoma, non-small 2017 (EU) & US 2016 (US) 2017 (EU) Truxima (rituximab), humanized IgG1 against cell surface antigen CD20, produced in CH0 cells Coll (SD) Selected cancers and autoim- mune disorders 2017 (EU) Truxima (rituximab), human IgG1 that selectively binds the p1 2018 (US) Janssen-Ciag (Berze, Belgium) Poriasis 2017 (EU) Zinplava (bezidoxumab), human IgG1 against cell surface antigen CD20, produced in CH0 cells Celliforin Merck Sharp & Dohme mure disorders 2017 (EU) Zinplava (bezidoxumab), human IgG1 against Coll softwall difficit otim IB, produced in CH0 cells Celliforin Merck Sharp & Dohme mure disorders 2016 (US) Zinplava (bezidoxumab), human IgG1 against Coll softwall difficit otim IB, produced in CH0 cells Europe Therapeutos (Pinetro Rago Cellifolito Inflammatory diseases 2016 (US) Zinplava (bezidoxumab), human IgG1 against Closs diffus angevita (cadalimu	Truxima (see above and below) Rixathon (rituximab), chimeric IgG1 against cell surface antigen		Various conditions including	2017 (EU)
uct as Rizathon (see above) toid arthritis, but excluding CLL Solymbic (additional), intrama IgG 1 produced in CHO cells, biosimilar to Humira. Same product as Amgevita and Amgevita (see above) Amgen Europe Relematoid arthritis and selected additional inflammabry diseases 2017 (EU) Tecentriq (atezplizumab), humanized IgG1 specific for pro- grammed death Igand 1 (P0-L1), engineered to lack Fc givcos)- auton, produced in CHO cells Roche Registration (Grenzach- Whilen, Germany) Urothelial carcinoma, non-small- cell lung cancer 2017 (EU) Tremfya (gueselkumab), human IgG1 that selectively binds the p13 subanit of L-23, produced in CHO cells Selected cancers and autoim- mune disorders 2017 (EU) Truxima (rituximab) chimeri IgG1 against cell surface angine. CD20, produced in CHO cells Celltrion Selected cancers and autoim- mune disorders 2017 (EU) Zinplara (bacbitoxumab), human IgG di rected agains Clostridium difficil toxin B, produced in CHO cells Merck Sharp & Dohme Merck (Whitehouse Station, NI, USA) C. difficile Infection 2016 (US) Angen (Tousand Oaks, CA, USA) Eurys Therapeutics (Pine Brook, NI, USA) Inhalational anthrax 2016 (US) Daraziex (daratumumab), humanized IgG1 against Bacillus anthracis (gea above) Eurys Therapeutics (Pine Brook, NI, USA) Inhalational anthrax 2016 (US) Daraziex (daratumumab), humanized IgG1 against the cell surface receptor SLAMF7, produced in NSO cells Samsung Bioepis (Chersey, UK) Multiple myeloma 2016 (UD) Dir cell	uct as Riximyo (see below) Riximyo (rituximab), chimeric IgG1 against cell surface antigen	Sandoz	rheumatoid arthritis Various conditions including non-	2017 (EU)
Amjerita (see above and below) Roche Registration (Grenzach-Wyhlen, Germany) Urothelial carcinoma, non-small- 2017 (EU) 2017 (EU) ation, produced in CHO cells Francisso, CA, USA) Urothelial carcinoma, non-small- 2017 (EU) 2017 (EU) Tremty (guselkumab), human igG1 that selectively binds the p19 Jansen Bitoteh (Horsham, PA, USA) Psoriasis 2017 (EU) Tructima (rituximab) chimeric igG1 against cell surface antigen (CD20, produced in CHO cells, biosimilar to MabThera, Same produ- uct as Bitzma, Ritemvia, and Tructima (see above) Celltrion Selected cancers and autoim- mune disorders 2017 (EU) Amjevita (adalimumab-atb), rh IgG1 specific for TNF, produced in CHO cells, biosimilar to MabThera, Same produ- uct as Bitzma, Ritemvia, and Tructima (see above) Amgen (Thousand Oaks, CA, USA) Rheumatoid arthritis and selected additional inflammatory diseases 2016 (US) Amjevita (adalimumab-atb), rh IgG1 specific for TNF, produced in CHO cells, biosimilar to Humins. Same product as Solymbic and Amgerita (see above) Amgen (Thousand Oaks, CA, USA) Rheumatoid arthritis and selected additional inflammatory diseases 2016 (US) Cho cells, biosimilar to Humins, Same product as Solymbic and Amgerita (see above) Linyar Phraepeutics (Pine Brook, NJ, USA) Rheumatoid arthritis and selected additional inflammatory diseases 2016 (US) Daratex (daratumumab), human IgG1 against CD-38, produced in HO cells Jansene-fiag Jansene Fiolech Multiple myeloma	uct as Rixathon (see above) Solymbic (adalimumab), anti-TNF human IgG1 produced in		toid arthritis, but excluding CLL Rheumatoid arthritis and selected	2017 (EU)
Tremfya (guselkumab), human lgG1 that selectively binds the p19 subunit of IL-23, produced in CHO cells Janssen-Cilag (Beerse, Belgium) Janssen Biotech (Horsham, PA, USA) Psoriasis 2017 (EU & US, Janssen Biotech (Horsham, PA, USA) Truxima (rituximab) chimeric IgG1 against cell surface antigen CD20, produced in CHO cells Cellition Selected cancers and autoim- mune disorders 2017 (EU) Zinplava (bezlotxumab), human IgG directed against Clostridium (Hifcife toxin B, produced in CHO cells Merck Sharp & Dohme C. difficile infection 2017 (EU) Amjevita (adalimumab-atto), rh IgG1 specific for TNF, produced in CHO cells, biosimilar to Humira. Same product as Solymbic and Anthim (obiltoxaximab), chimeric IgG1 against <i>Bacillus anthracis</i> toxin, produced in NSO cells Merck Sharp & Dohme Reumatoid arthritis and selected additional inflammatory diseases 2016 (US) Dazatex (daratumumab), chimeric IgG1 against Bacillus anthracis toxin, produced in NSO cells Elusys Therapeutics (Pine Brook, NJ, USA) Inhalational anthrax 2016 (US) Dazatex (daratumumab), human IgG1 against CD-38, produced in CHO cells, biosimilar to Remicade Same product as Renflexis Janssen Cilag Multiple myeloma 2016 (EU) Dazatex (daratumumab), human igG1 against the cell surface receptor SLAMF7, produced in NSO cells Samsung Bioepis (Chertsey, UK) Multiple myeloma (in combina- tion with lenalidomide and dexa- antylosing spondylitis 2016 (EU) Finzbi (infliximab), chimeric IgG1 against the	Amjevita (see above and below) Tecentriq (atezolizumab), humanized IgG1 specific for pro- grammed death ligand 1 (PD-L1), engineered to lack Fc glycosyl-	Wyhlen, Germany) Genentech (South San	Urothelial carcinoma, non-small-	
Truxima (rituximab) chimeric IgG1 against cell surface antigen CD20, produced in CHO cells, biosimilar to MabThera. Same prod- uct as Biltizma, Riterwia, and Truxima (see above) Celltrion Selected cancers and autoim- mune disorders 2017 (EU) Zinplava (bezlotoxumab), human IgG directed against <i>Clostridium difficile</i> toxin B, produced in CHO cells Merck Sharp & Dohme Merck (Whitehouse Station, NJ, USA) <i>C. difficile</i> infection 2017 (EU) Amjevita (adalimumab-atto), rh IgG1 specific for TNF, produced in CHO cells, biosimilar to Humin: Same product as Solymbic and Amgevita (see above) Amgen (Thousand Oaks, CA, USA) Rheumatoid arthritis and selected additional inflammatory diseases 2016 (US) Anthim (obiitoxarimab), chimeric IgG1 against <i>Bacillus anthracis</i> toxin, produced in NSO cells Eurys Therapeutics (Pine Brook, NJ, USA) Inhalational anthrax 2016 (US) Darzalex (daratumumab), human IgG1 against CD-38, produced in CHO cells Janssen-Cilag Janssen-Cilag Multiple myeloma 2016 (EU) Empliciti (elotuzumab), humanized IgG1 against the cell surface receptor SLAMF7, produced in NSO cells Bristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA) Multiple myeloma (in combina- anke)soing aro Arthritis, pso- riasis, colits, corchi's disease, ankylosing spondylitis 2016 (EU) Fitabi (infliximab), chimeric IgG1 against TNF-a, produced in murine Sp2/0 cells, biosimilar to Remicade Inflectra: Hospira (Lake Forest, IL, USA), Celltrion (Incheon, Republic of Korea) and Hospira; (Reyal Learnington Sp. UK); Remsima: Celltrion		Janssen-Cilag (Beerse, Belgium) Janssen Biotech (Horsham, PA,	Psoriasis	2017 (EU & US)
difficile toxin B, produced in CHO cellsMerck (Whitehouse Station, NJ, USA)2016 (US)Amjevita (adalimumab-atto), rh IgG1 specific for TNF, produced in CHO cells, biosimilar to Humira. Same product as Solymbic and Amgevita (see above)Amgen (Thousand Oaks, CA, USA)Rheumatoid arthritis and selected additional inflammatory diseases2016 (US)Anthim (obiltoxaximab), chimeric IgG1 against <i>Bacillus anthracis</i> toxin, produced in NSO cellsElusys Therapeutics (Pine Brook, NJ, USA)Inhalational anthrax2016 (US)Cinqair in US, Cinqaero in EU (reslizumab), humanized IgG4 against LL-5, produced in NSO cellsTeva Respiratory (Frazer, PA Janseen CilagAsthma2016 (EU)Darzalex (daratumumab), humanized IgG1 against CD-38, produced in CHO cellsJanssen Cilag Janssen CilagMultiple myeloma (in combina- toni wti henalidomide and dexa- methasone)2016 (EU)Empliciti (elotuzumab) humanized IgG1 against TNF-a, produced in Receptor SLAMF7, produced in NSO cellsSamsung Bioepis (Chertsey, UK) Various forms of arthritis, pso- raiss, colifis, corbin's disease, ankylosing spondylitis2016 (EU)Flixabi (infliximab), chimeric IgG1 against TNF-a, produced in receptor SLAMF7, produced in NSO cellsInflectra: Hospira (Lake Forest, (Ryal Leamington Spa, UK); Republic of Korea) and Hospira (Ryal Leamington Spa, UK); <br< td=""><td>CD20, produced in CHO cells, biosimilar to MabThera. Same prod- uct as Blitzima, Ritemvia, and Truxima (see above)</td><td>Celltrion</td><td>mune disorders</td><td></td></br<>	CD20, produced in CHO cells, biosimilar to MabThera. Same prod- uct as Blitzima, Ritemvia, and Truxima (see above)	Celltrion	mune disorders	
CH0 cells, biosimilar to Humira. Same product as Solymbic and Amgevita (see above)USÅadditional inflammatory diseasesAnthim (oblitoxaximab), chimeric IgG1 against <i>Bacillus anthracis</i> toxin, produced in NSO cellsElusys Therapeutics (Pine Brook, NJ, USÅ)Inhalational anthrax2016 (US)Cinqair in US, Cinqaero in EU (reslizumab), humanized IgG4 against IL-5, produced in NSO cellsTeva Respiratory (Frazer, PA USÅ)Asthma2016 (EU)Darzalex (daratumumab), human IgG1 against CD-38, produced in CH0 cellsJanssen-Cilag Janssen BiotechMultiple myeloma2016 (EU)Empliciti (elotuzumab) humanized IgG1 against the cell surface receptor SLAMF7, produced in NSO cellsBristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA)Multiple myeloma2016 (EU) 2015 (US)Fitxabi (infliximab), chimeric IgG1 against TNF-a, produced in CH0 cells, biosimilar to Remicade. Same product as Renflexis (see above)Samsung Bioepis (Chertsey, UK) Various forms of arthritis, pso- riasis, colitis, Crohn's disease, ankylosing spondylitis2016 (EU) 2016 (EU)Inflectra in EU and US, Remsima in EU (infliximab in EU, inflix- imab-dyyb in US), chimeric IgG1 specific for TNF-a, produced in murine Sp2/0 cells, biosimilar to RemicadeInflectra: Hospira (Lake Forest, Reyal Lacamington Spa, UK), Remsima: Celltrion (Budapest)Cortain Grom of arthritis and pso- colitis, ankylosing spondylitis2016 (EU) 2016 (EU)Portrazza (necitumumab), rh IgG1 specific for human platelet-derived give of hactor receptor-a, produced in NSO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Sarcoma2016 (EU & US)Portrazza (necitumumab), humanized IgG4	difficile toxin B, produced in CHO cells	Merck (Whitehouse Station, NJ, USA)		2016 (US)
toxin, produced in NSO cellsNJ, USA)Cinqair in US, Cinqaero in EU (reslizumab), humanized IgG4 against IL-5, produced in NSO cellsTeva Respiratory (Frazer, PA USA) Teva (Haarlem, the Netherlands)Asthma2016 (EU) 2016 (EU)Darzalex (daratumumab), human IgG1 against CD-38, produced in CHO cellsJanssen-Cilag Janssen BiotechMultiple myeloma2016 (EU) 2015 (US)Empliciti (elotuzumab) humanized IgG1 against the cell surface receptor SLAMF7, produced in NSO cellsBristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA)Multiple myeloma (in combina- tom with lenaildomide and dexa- methasone)2016 (EU) 2015 (US)Flixabi (infliximab), chimeric IgG1 against TNF-α, produced in murine Sp2/O cells, biosimilar to Remicade. Same product as Renflexis (see above)Samsung Bioepis (Chertsey, UK) rasis, colitis, crohn's disease, ankylosing spondylitis2016 (EU) 2016 (EU) 2016 (EU) 2015 (US)Lartruvo (olaratumab), rh IgG1 specific for TNF-α, produced in murine Sp2/O cells, biosimilar to RemicadeInflix- num platelet-derived growth factor receptor-α, produced in NSO cellsIli (Utrecht, the Netherlands, & Indianapolis)Sarcoma2016 (EU & US) 2016 (EU & US)Portazza (necitumumab), human IgG1 against the ligand binding site of human EGF receptor, produced in NSO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Non-small-cell lung cancer (in combination with gencitabine and cisplatin)2016 (EU & US) 2016 (EU & US)Taltz (ixekizumab), humanized IgG1 against IL-2Rα, produced in NSO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Poriasis2016 (EU & US) 2016 (EU & US)	CHO cells, biosimilar to Humira. Same product as Solymbic and Amgevita (see above)	USA)	additional inflammatory diseases	
Teva (Haarlem, the Netherlands)Darzalex (daratumumab), human IgG1 against CD-38, produced in CHO cellsJanssen BiotechMultiple myeloma2016 (EU) 2015 (US)Empliciti (elotuzumab) humanized IgG1 against the cell surface receptor SLAMF7, produced in NS0 cellsBristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA)Multiple myeloma2016 (EU) 2015 (US)Flixabi (infliximab), chimeric IgG1 against TNF-α, produced in CHO cells, biosimilar to Remicade. Same product as Renflexis (see above)Samsung Bioepis (Chertsey, UK)Various forms of arthritis, pso- riasis, colitis, Crohn's disease, ankylosing spondylitis2016 (EU) 2015 (US)Inflectra in EU and US, Remsima in EU (infliximab in EU, inflix- imab-dyyb in US), chimeric IgG1 specific for TNF-α, produced in murine Sp2/0 cells, biosimilar to RemicadeInflectra: Hospira (Lake Forest, IL, USA), Celtrion (Incheon, Republic of Korea) and Hospira (Royal Leamington Spa, UK); Remsima: Celltrion (Budapest)Certain forms of arthritis and pso- riasis, crohn's disease, ulcerative, colitis, ankylosing spondylitis2016 (EU sus)Lartruvo (olaratumab), rh IgG1 specific for human platelet-derived growth factor receptor-α, produced in NS0 cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Sarcoma2016 (EU sus) combination with gemcitabine and cisplatin)Tetru (ixekizumab), humanized IgG4 against hll-17A, produced in CHO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Poriasis2016 (EU & US) combination with gemcitabine and cisplatin)Taltz (ixekizumab), humanized IgG1 against HL-2Rα, produced in NSO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis) <t< td=""><td>toxin, produced in NSO cells Cinqair in US, Cinqaero in EU (reslizumab), humanized IgG4</td><td>NJ, USA) Teva Respiratory (Frazer, PA</td><td></td><td>2016 (US)</td></t<>	toxin, produced in NSO cells Cinqair in US, Cinqaero in EU (reslizumab), humanized IgG4	NJ, USA) Teva Respiratory (Frazer, PA		2016 (US)
in CHO cellsJanssen Biotech2015 (US)Empliciti (elotuzumab) humanized IgG1 against the cell surface receptor SLAMF7, produced in NSO cellsBristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA)Multiple myeloma (in combina- tion with lenalidomide and dexa- methasone)2016 (EU) 2015 (US)Flixabi (infliximab), chimeric IgG1 against TNF-α, produced in CHO cells, biosimilar to Remicade. Same product as Renflexis 	Darzalex (daratumumab), human IgG1 against CD-38, produced	Teva (Haarlem, the Netherlands) Janssen-Cilag	Multiple myeloma	2016 (EU)
Flixabi (infliximab), chimeric IgG1 against TNF-α, produced in CHO cells, biosimilar to Remicade. Same product as Renflexis (see above)Samsung Bioepis (Chertsey, UK)Various forms of arthritis, pso- riasis, colitis, Crohn's disease, 	in CHO cells Empliciti (elotuzumab) humanized IgG1 against the cell surface	Janssen Biotech Bristol-Myers Squibb (Uxbridge,	Multiple myeloma (in combina- tion with lenalidomide and dexa-	2015 (US) 2016 (EU)
Inflectra in EU and US, Remsima in EU (infliximab in EU, inflix- imab-dyyb in US), chimeric IgG1 specific for TNF-α, produced in murine Sp2/0 cells, biosimilar to RemicadeInflectra: Hospira (Lake Forest, L, USA), Celltrion (Incheon, Republic of Korea) and Hospira (Royal Learnington Spa, UK); Remsima: Celltrion (Budapest)Certain forms of arthritis and pso- riasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis2016 (US) 2013 (EU)Lartruvo (olaratumab), rh IgG1 specific for human platelet-derived growth factor receptor-α, produced in NSO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Sarcoma2016 (EU & US)Portrazza (necitumumab), human IgG1 against the ligand binding site of human EGF receptor, produced in NSO cellsEli Lilly (Utrecht, the 	CHO cells, biosimilar to Remicade. Same product as Renflexis	Samsung Bioepis (Chertsey, UK)	Various forms of arthritis, pso- riasis, colitis, Crohn's disease,	2016 (EU)
Lartruvo (olaratumab), rh IgG1 specific for human platelet-derived growth factor receptor-α, produced in NS0 cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Sarcoma2016 (EU & US)Portrazza (necitumumab), human IgG1 against the ligand binding site of human EGF receptor, produced in NS0 cellsEli Lilly (Utrecht, the 	Inflectra in EU and US, Remsima in EU (infliximab in EU, inflix- imab-dyyb in US), chimeric IgG1 specific for TNF- α , produced in	IL, USA), Celltrion (Incheon, Republic of Korea) and Hospira (Royal Leamington Spa, UK);	Certain forms of arthritis and pso- riasis, Crohn's disease, ulcerative	
site of human EGF receptor, produced in NSO cellsNetherlands, & Indianapolis)combination with gemcitabine and cisplatin)2015 (US)Taltz (ixekizumab), humanized IgG4 against hIL-17A, produced in CHO cellsEli Lilly (Utrecht, the Netherlands, & Indianapolis)Psoriasis2016 (EU & US)Zinbryta (daclizumab), humanized IgG1 against IL-2Rα, produced in NSO cellsBiogen (Cambridge, MA US) Biogen Idec (Maidenhead, UK)Multiple sclerosis Withdrawn 2018	growth factor receptor-α, produced in NSO cells	Eli Lilly (Utrecht, the Netherlands, & Indianapolis)		2016 (EU & US)
Zinbryta (daclizumab), humanized IgG1 against IL-2Rα, produced in NS0 cells Biogen (Cambridge, MA US) Biogen Idec (Maidenhead, UK) Multiple sclerosis 2016 (EU & US) Withdrawn 2018	site of human EGF receptor, produced in NSO cells Taltz (ixekizumab), humanized IgG4 against hIL-17A, produced in	Netherlands, & Indianapolis) Eli Lilly (Utrecht, the	combination with gemcitabine and cisplatin)	
	Zinbryta (daclizumab), humanized IgG1 against IL-2Rα, produced	Biogen (Cambridge, MA US)	Multiple sclerosis	2016 (EU & US) Withdrawn 2018 (EU & US)

Table 1. Continued				Table 1. Continued			
Table 1 Continued Product Blincyto (blinatumomab), bispecific T-cell engager antibody con- struct (BiTE), produced in CHO cells	Company (location) Amgen Europe Amgen (Thousand Oaks, CA,	Therapeutic indication Acute lymphoblastic leukemia	Date approved 2015 (EU) 2014 (US)	Table 1 Continued Product Humaspect (votumumab), human mAb against cytokeratin tumorassociated antigen, produced in a human lymphoblastoid cell line	Company (location) KS Biomedix (Farnham, UK)	Therapeutic indication Detection of carcinoma of the colon or rectum	Date approved 1998 (EU) Withdrawn 2004
Cosentyx (secukinumab), human IgG1 selectively binding human IL-17a, produced in CHO cells	USA) Novartis Europharm (Camberley, UK)	Moderate to severe plaque psoria- sis in adults	2015 (EU & US)	MabThera in EU, Rituxan in US (rituximab), chimeric mAb against CD20 surface antigen of B lymphocytes, produced in CHO cells Simulect (basiliximab), chimeric mAb directed against the α-chain		Non-Hodgkin lymphoma	1998 (EU) 1997 (US) 1998 (EU)
Keytruda (pembrolizumab), humanized IgG4 capable of binding to the receptor PD-1, produced in CHO cells	Novartis (East Hanover, NJ, USA) Merck Sharp & Dohme Merck (Whitehouse Station, NJ,	Advanced (unresectable or meta- static) melanoma in adults	2015 (EU) 2014 (US)	of the IL-2 receptor, produced in a murine myeloma cell line	Immunomedics (Darmstadt,	Prophylaxis of acute organ rejec- tion in allogeneic renal trans- plantation Diagnostic imaging for infection	1998 (EU) 1997 (EU)
Nivolumab BMS (nivolumab), human IgG4 against the receptor PD-1, produced in CHO cells. Same product as Opdivo (see below)	USA) Bristol-Myers Squibb (Uxbridge, UK)	Locally advanced or metastatic squamous non-small-cell lung	July 2015 (EU) Withdrawn	locyte surface nonspecific cross-reacting antigen-90, produced in Sp2/0 cells Verluma (nofetumomab), murine mAb Fab fragment directed	Germany) Boehringer Ingelheim, NeoRx	and inflammation in bone of patients with osteomyelitis Detection of small-cell lung	Withdrawn 2018 1996 (US)
Nucala (mepolizumab), humanized IgG1 capable of binding human IL-5, produced in CHO cells	GlaxoSmithKline (Cork, Ireland) GSK (Research Triangle Park,	cancer after prior chemotherapy in adults Add-on treatment for severe refractory eosinophilic asthma in	November 2015	against carcinoma-associated antigen, produced in a murine cell line Tecnemab KI (antimelanoma Mab fragments), murine mAb frag-	(Seattle) Amersham Sorin (Milan)	cancer Diagnosis of cutaneous mela-	Withdrawn 1999 1996 (EU)
Opdivo (nivolumab), human IgG4 against the receptor PD-1, pro- duced in CHO cells. Same product as nivolumab BMS (see above)	Bristol-Myers Squibb (Uxbridge, UK, & Princeton, NJ, USA)	Adult patients Melanoma (as monotherapy or in combination with ipilimumab),	2015 (EU) 2014 (US)	ments (Fab/Fab ₂ mix) against HMW-MAA, produced in murine ascites culture ProstaScint (capromab pentetate), murine mAb against the tumor	EUSA Pharma USA (Langhorne,	noma lesions Detection, staging and follow-up	Withdrawn 2000 1996 (US)
Praluent (alirocumab), human IgG1 targeting PCSK9, produced in	Sanofi-Aventis (Paris &	combination with philinanab, non-small-cell lung cancer, renal cell carcinoma Primary hypercholesterolemia	2015 (EU & US)	surface antigen PSMA, produced in a murine cell line MyoScint (imiciromab pentetate), murine mAb fragment directed against human cardiac myosin, produced in a murine cell line	PA, USA) Centocor	of prostate adenocarcinoma Myocardial infarction imaging	1996 (US) Withdrawn 1999
CHO cells	Bridgewater, NJ, USA) Regeneron Pharmaceuticals (Tarrytown, NY, USA)	or mixed dyslipidemia, as an adjunct to diet	2013 (20 & 03)	CEA-scan (arcitumomab), murine mAb Fab fragment against human carcinoembryonic antigen (CEA), produced in mouse asci- tes	Immunomedics	Detection of recurrent or meta- static colorectal cancer	1996 (EU & US) Withdrawn 2005 (EU & US)
Praxbind (idarucizumab), humanized IgG1 Fab fragment capable of binding the anticoagulant drug dabigatran, produced in CHO cells	Boehringer Ingelheim (Rhein, Germany, & Ridgefield, CT, USA)	Rapid reversal agent for the anti- coagulant drug dabigatran	2015 (EU & US)	Indimacis 125 (igovomab), murine mAb Fab ₂ fragment against the tumor-associated antigen CA125, produced in a murine cell line	CIS Bio (Gif-sur-Yvette, France)	Diagnosis of ovarian adenocar- cinoma	1996 (EU) Withdrawn 2009
Repatha (evolocumab), human IgG2 capable of binding human PCSK-9, produced in CHO cells	Amgen Europe Amgen (Thousand Oaks, CA, USA)	Hypercholesterolemia and mixed dyslipidemia	2015 (EU & US)	ReoPro (abciximab), Fab fragments derived from a chimeric mAb against the platelet surface receptor GPII _b /III _, produced in a mammalian cell line	Janssen Biologics (Leiden, the Netherlands), Centocor	Prevention of blood clots	1994 (US)
Unituxin (dinutuximab), chimeric IgG1 targeting human disialo- ganglioside (GD2), produced in Sp2/0 cells	United Therapeutics (Chertsey, UK, & Silver Spring, MD, USA)	Neuroblastoma (administered in combination with GM-CSF, IL-2 and isotretinoin)	2015 (EU & US) Withdrawn 2017 (EU)	OncoScint CR/OV (satumomab pendetide), murine mAb against the tumor-associated glycoprotein TAG-72, produced in a murine cell line	Cytogen (Princeton, NJ, USA)		1992 (US) Withdrawn 2002
Cyramza (ramucirumab), human mAb that binds the VEGF-2 receptor, produced in NSO cells	Eli Lilly Nederland (Utrecht, the Netherlands) Eli Lilly (Indianapolis)	Gastric cancer	2014 (EU & US)	Orthoclone OKT3 (muromomab CD3), murine mAb against the T-lymphocyte surface antigen CD3, produced in a murine cell line	Centocor Ortho Biotech Products (Raritan, NJ, USA)	Reversal of acute kidney trans- plant rejection	1986 (US)
Entyvio (vedolizumab), humanized IgG targeting the human $\alpha 4\beta 7$ integrin, produced in CHO cells	Takeda Pharmaceuticals (Deerfield, IL, USA) Takeda Pharma (Taastrup,	Ulcerative colitis, Crohn's disease	2014 (EU & US)	Other recombinant products Bone morphogenetic proteins Opgenra (eptotermin alfa), rh BMP-7, produced in CHO cells	Olympus Biotech (Limerick, Ireland)	Posterolateral lumbar spinal fusion	2009 (EU) Withdrawn 2016
Gazyva in US, Gazyvaro in EU (obinutuzumab), humanized, gly- coengineered mAb specific for B-cell antigen CD20, produced in	Denmark) Roche/Genentech Roche (Welwyn Garden City, UK)	CLL	2014 (EU) 2013 (US)	Infuse bone graft, containing dibotermin alfa, a rh BMP-2 pro- duced in CHO cells, placed on an absorbable collagen sponge.	Wyeth (Madison, NJ, USA)	Acute open tibial shaft fracture	2004 (US)
CHO cells Sylvant (siltuximab), chimeric mAb that binds human IL-6, pro- duced in CHO cells	Janssen Biotech	Multicentric Castleman disease	2014 (EU & US)	Active substance same as that in Infuse (see below) Inductos (dibotermin alfa), rh BMP-2, produced in CHO cells	Medtronic BioPharma (Heerlen, the Netherlands)	Acute tibia fractures	2002 (EU)
Kadcyla (trastuzumab emtansine), humanized mAb specific for HER2 antigen, produced in CHO cells and conjugated to the small molecule cytotoxin DM1	Roche (Welwyn Garden City, UK)	Breast cancer	2013 (EU & US)	Infuse (rh BMP2), produced in CHO cells	Wyeth Europa Genetics Institute Medtronic Sofamor Danek	Promotes fusion of lower spine	2002 (US)
Simponi Aria (golimumab). Active substance same as that in Simponi (see below); different strength and mode of administration	Janssen Biotech	Rheumatoid arthritis	2013 (US)	OP-1 implant in US, Osigraft in EU (eptotermin alfa), rh BMP-7, produced in CHO cells	(Memphis, TN, USA) Olympus Biotech (Limerick, Ireland) Stytker Biotech (Henkinton, MA	vertebrae Non-union of tibia	2001 (EU & US) Withdrawn 2015
Perjeta (pertuzumab), human mAb specific for HER2, produced in CHO cells Abthrax (raxibacumab), human IgG mAb against the protective	Roche/Genentech GSK/Human Genome Sciences	Breast cancer Inhalational anthrax	2013 (EU) 2012 (US) 2012 (US)	Recombinant enzymes	Stryker Biotech (Hopkinton, MA, USA)		(EU)
Adcetris (brentuximab vedotin), chimeric mAb conjugate specific for human CD30 (expressed on the surface of lymphoma cells),	(Rockville, MD, USA) Takeda Pharma (Roskilde, Denmark)	Lymphoma	2012 (EU) 2011 (US)	Palynziq (pegvaliase-pqpz), r phenylalanine ammonia lyase, pro- duced in <i>E. coli</i> and PEGylated Lamzede (velmanase alfa), rh α-mannosidase, expressed in precur-	BioMarin (Novato, CA, USA) Chiesi Farmaceutici (Parma,	Phenylketonuria α-mannosidosis	2018 (US) 2018 (EU)
produced in CHO cells Benlysta (belimumab), human mAb that targets human B-lymphocyte stimulator (BLyS), a B cell survival factor. produced	Seattle Genetics Human Genome Sciences Glaxo Group (Greenford, UK)	Lupus	2011 (EU & US)	sor form in CHO cells Brineura (cerliponase alfa), rh serine tripeptidyl peptidase-1,	BioMarin (Cork, Ireland),	CLN2 disease (tripeptidyl pepti-	2018 (EU) 2017 (EU & US)
in NSO cells Xgeva (denosumab) (see Prolia)	Amgen Europe	Bone loss associated with cancer	2011 (EU) 2010 (US)	expresses in proenzyme form in CHO cells Mepsevii (vestronidase alfa-vjbk), r human lysosomal β-glucuronidase, produced in CHO cells	Ultragenyx Pharmaceutical (Novato, CA, USA)	dase-1 deficiency) Mucopolysaccharidosis VII	2017 (US)
Yervoy (ipilimumab), human mAb binding to CTLA-4 (a negative regulator of T-cell activation), thereby enhancing T cell activation and proliferation, produced in CHO cells	Bristol-Myers Squibb (Uxbridge, UK)	Melanoma	2011 (EU & US)	Oncaspar (pegaspargase), r asparaginase, produced in <i>E. coli</i> and conjugated to monomethoxypropylene glycol Spectrila (asparaginase), r asparaginase, produced in <i>E. coli</i>	Baxalta Innovations Medac Gesellschaft für klinische	Lymphoblastic leukemia, lym- phoma Lymphoblastic leukemia, lym-	2016 (EU) 2016 (EU)
Actemra in US, RoActemra in EU (tocilizumab), humanized mAb specific for IL-6, produced in a mammalian cell line	Roche (Welwyn Garden City, UK)		2010 (US) 2009 (EU)	Kanuma (sebelipase alfa), rh lysosomal acid lipase, produced in	Spezialpräparate (Wedel, Germany) Alexion Europe (Rueil-	phoma Enzyme replacement therapy	2015 (EU & US)
Arzerra (ofatumumab), human mAb specific for CD20, produced in NS0 hybridoma cells	USA), Genmab (Greenford, UK)	CLL	2010 (EU) 2009 (US)	the eggs of transgenic chickens	Malmaison, France) Alexion Pharmaceuticals (Cheshire, CT, USA)	in patients with lysosomal acid lipase deficiency	
Prolia (denosumab), human mAb specific for receptor activator of nuclear factor κ B ligand (RANKL), produced in CHO cells Scintimun (besilesomab), murine mAb against nonspecific cross-reacting antigen-95 (found on surface of granulocytes), produced	Amgen Europe CIS Bio International (Gif-sur- Yvette, France)	Osteoporosis in postmenopausal women <i>In vivo</i> diagnosis or investigation of sites of inflammation or infec-	2010 (EU & US) 2010 (EU)	Strensiq (asfotase alfa), dimeric fusion protein containing a solu- ble catalytic domain of human tissue nonspecific alkaline phos- phatase linked to an IgG Fc domain and a deca-aspartate peptide domain, produced in CHO cells	Alexion Europe (Rueil- Malmaison, France) Alexion (Cheshire, CT, USA)	Enzyme replacement therapy in patients with pediatric-onset hypophosphatasia	2015 (EU & US)
in hybridoma cells Cimzia (certolizumab pegol), anti-TNF-α humanized and PEGylated antibody Fab' fragment, produced in <i>E. coli</i>	UCB Pharma (Brussels, Belgium)	tion via scintigraphic imaging Crohn's disease, rheumatoid arthritis	2009 (EU) 2008 (US)	Vimizim (elosulfase alfa), rh N-acetlygalactosamine-6-sulfatase, produced in CHO cells Krystexxal (pegloticase), r urate oxidase, PEGylated after synthe-	BioMarin (London, UK) Savient Pharma Ireland (Dublin)	Mucopolysaccharidosis IVA (Morquio A syndrome) Gout	2014 (EU & US) 2013 (EU)
llaris (canakinumab), human mAb specific for IL-1 $\beta,$ produced in Sp2/0 cells	Novartis Pharmaceuticals (East Hanover, NJ, USA) Novartis Europharm (Dublin)	Cryopyrin-associated periodic syndromes (CAPS)	2009 (EU & US)	sis, produced in <i>E. coli</i>	Crealta Pharmaceuticals (Lake Forest, IL, USA)		2010 (US) Withdrawn 2016 (EU)
Removab (catumaxomab), bispecific engineered antibody target- ing the human epithelial cell adhesion molecule and human CD3 expressed on T-lymphocytes, produced in hybridoma cells	Neovii Biotech (Gräfelfing, Germany)	Malignant ascites in patients with carcinomas expressing epithelial cell adhesion molecule		Elelyso (taliglucerase alfa), rh glucocerebrosidase, produced in engineered carrot root cell culture Voraxaze (glucarpidase), r carboxypeptidase, produced in <i>E. coli</i>	Pfizer (New York), Protalix BioTherapeutics (Karmiel, Israel) BTG International (West	Gaucher disease Toxic plasma methotrexate	2012 (US) 2012 (US)
Simponi (golimumab), human mAb specific for TNF- α , produced in Sp2/O cells	Janssen Biologics (Leiden, the Netherlands) Janssen Biotech (Horsham, PA, USA)	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis	2009 (EU & US)	lumizumo (algluopeidase alfa), rh peid a gluopeidase, produced in	Conshohocken, PA, USA)	concentrations in patients with delayed methotrexate clearance due to impaired renal function	2010 (US)
Stelara (ustekinumab), human MAb specific for the p40 subunit of IL-12 and IL-23, produced in Sp2/0 cells	Janssen-Cilag	Moderate to severe plaque pso- riasis	2009 (EU & US)	Lumizyme (alglucosidase alfa), rh acid-α-glucosidase, produced in CHO cells VPRIV (velaglucerase alfa), rh glucocerebrosidase, produced in a	Shire Human Genetic Therapies	Pompe disease (glycogen storage disease type II) Gaucher disease	2010 (US) 2010 (EU & US)
Lucentis (ranibizumab), humanized IgG fragment that binds and inactivates VEGF-A, produced in E. coli Soliris (eculizumab), humanized IgG that binds human C5 comple-		Neovascular (wet) age-related macular degeneration Paroxysmal nocturnal hemoglo-	2007 (EU) 2006 (US) 2007 (EU & US)	human fibroblast cell line Elaprase (idursulfase), rh iduronate-2-sulfatase, produced in a human cell line	(Danderyd, Sweden) Shire Human Genetic Therapies	syndrome)	2006 (US)
ment protein, produced in a murine myeloma cell line Vectibix (panitumumab), human mAb that binds to human EGF receptor, produced in CHO cells	(Cheshire, CT, USA, & Paris) Amgen Europe Abgenix	binuria EGF receptor–expressing colorec- tal carcinoma	2007 (EU) 2006 (US)	Naglazyme (galsulfase), rh N-acetylgalactosamine-4-sulfatase, produced in CHO cells	BioMarin (London & Novato, CA, USA)	Long-term enzyme replacement therapy in mucopolysaccharido- sis VI	2006 (EU) 2005 (US)
Tysabri (natalizumab), humanized mAb against selected leukocyte integrins, produced in murine myeloma cells	Biogen Inc. (Cambridge, MA, USA) Biogen Netherlands	Relapsing forms of multiple sclerosis	2006 (EU) 2004 (US) Suspended	Myozyme (algulcosidase alfa), rh acid glucosidase, produced in CHO cells Aldurazyme (laronidase), r α -L-iduronidase, produced in CHO cells	Sanofi Genzyme (Naarden, the Netherlands) BioMarin		2006 (EU & US) 2003 (EU & US)
	(Badhoevedorp, the Netherlands)	Madanak karanan analisinak	2005 (US) Resumed 2006 (US)	Hylenex (hyaluronidase), rh hyaluronidase, produced in CHO cells	Halozyme Therapeutics (San Diego)	polysaccharidosis I Adjuvant to increase absorption and dispersion of other drugs	2005 (US)
Xolair (omalizumab), humanized mAb that binds IgE at the site of high-affinity IgE receptor binding, produced in CHO cells Zevalin (ibritumomab tiuxetan), murine mAb against the CD20	Roche/Genentech Spectrum Pharmaceuticals	Moderate to severe persistent asthma in adults and adolescents Non-Hodgkin lymphoma	2005 (EU) 2003 (US) 2004 (EU)	Fabrazyme (agalsidase beta), rh α-galactosidase, produced in CHO cells Replagal (agalsidase alfa), rh α-galactosidase, produced in a	Sanofi Genzyme (Naarden, the Netherlands) Shire Human Genetic Therapies,	deficiency)	2003 (US) 2001 (EU) 2001 (EU)
antigen, produced in CHO cells Erbitux (cetuximab), chimeric mAb against human EGF receptor, produced in Sp2/O cells	(Amsterdam) Merck KGaA (Darmstadt, Germany) Fili Lilly (Indianapolis)	EGF receptor-expressing meta- static colorectal cancer	2002 (US) 2004 (EU & US)	human cell line Fasturtec in EU, Elitex in US (rasburicase), r urate oxidase, pro- duced in <i>S. cerevisiae</i>	TKT Europe Sanofi (Paris)	deficiency) Hyperuricemia	2002 (US) 2001 (EU)
Raptiva (efalizumab), humanized mAb that binds to LFA-1, which is expressed on all leukocytes; produced in CHO cells	Eli Lilly (Indianapolis) Serono (London, UK) Genentech	Chronic moderate to severe plaque psoriasis in adults	2004 (EU) 2003 (US) Withdrawn 2009	Cerezyme (imiglucerase), rh β -glucocerebrosidase, produced in CHO cells Pulmozyme (dornase alpha), r DNase, produced in CHO cells	Genzyme (Naarden, the Netherlands) Roche/Genentech	Gaucher disease Cystic fibrosis	1997 (EU) 1994 (US) 1993 (US)
Avastin (bevacizumab), humanized mAb against VEGF, produced in CHO cells	Roche/Genentech (Welwyn Garden City, UK)	Metastatic colorectal cancer, glioblastoma, metastatic renal	Withdrawn 2009 2005 (EU) 2004 (US)	Fusion proteins Erelzi (etanercept in EU, etanercept-szzs in USA), r dimeric fusion	Sandoz (Kundl, Austria, &	Rheumatoid arthritis, selected	2017 (EU)
NeutroSpec (fanolesomab), murine mAb against CD15, a surface antigen of selected leukocytes, produced in hybridoma cells	Palatin Technologies (Cranbury, NJ, USA), Mallinckrodt Pharmaceuticals (Hazelwood,	carcinoma Imaging of equivocal appendicitis	2004 (US) Withdrawn 2005	protein consisting of TNF receptor extracellular domains linked to an IgG1 Fc region, produced in CHO cells, biosimilar to Enbrel Lifmior (etanercept), r dimeric fusion protein consisting of TNF	Princeton, NJ, USA) Pfizer Europe (Brussels)	cher inflammatory diseases	2017 (EU) 2016 (US) 2017 (EU)
Humira in EU & US, Trudexa in EU (adalimumab), anti-TNF human mAb, produced in CHO cells	MO, USA) AbbVie (Maidenhead, UK)	Rheumatoid arthritis	2003 (EU) 2002 (US)	receptor extracellular domains linked to an IgG1 Fc region, pro- duced in CHO cells. Same product as Enbrel (see below) Benepali (etanercept), rh TNF receptor–IgG Fc fusion protein, pro-	Samsung Bioepis (Chertsey, UK)	other inflammatory diseases	2016 (EU)
			Trudexa with- drawn 2007 (EU)	duced in CHO cells, biosimilar to Enbrel Zaltrap (aflibercept), combination drug consisting of binding domains of VEGF receptors 1 and 2 fused to an IgG Fc, produced	Sanofi (Paris) Sanofi-aventis US (Bridgewater, NJ, USA)	Ioarthritis Metastatic colorectal cancer	2013 (EU) 2012 (US)
Bexxar (tositumomab), radiolabeled mAb against CD20, produced in murine hybridoma cells Mabcampath (EU) or Campath (US) (alemtuzumab), humanized	Genzyme (Naarden, the	CD20-positive follicular non- Hodgkin lymphoma CLL	2003 (US) Withdrawn 2014 2001 (EU & US)	in CHO cells. Same active substance as in Eylea (see below) Eylea (aflibercept), fusion protein consisting of extracellular ligand binding domains of VEGF receptor fused to IgG Fc, produced in	Bayer (Berlin) Regeneron Pharmaceuticals	Neovascular (wet) age-related macular degeneration	2012 (EU) 2011 (US)
mAb against CD52, a surface antigen of B lymphocytes, produced in CHO cells	Netherlands) Millennium (Cambridge, MA, USA)		Withdrawn (EU) 2012	CHO cells). Same active substance as in Zaltrap (see above) Nulojix (belatacept), fusion protein consisting of the extracellular domain of human CTLA4 fused to IgG Fc; binds CD80 and CD86	(Tarrytown, NY) Bristol-Myers Squibb (Uxbridge, UK)	Prophylaxis of organ rejection fol- lowing kidney transplant	
Herceptin (trastuzumab), humanized mAb against HER2, pro- duced in a murine cell line	Roche (Welwyn Garden City, UK)	Treatment of metastatic breast cancer overexpressing HER2 protein	2000 (EU) 1998 (US)	on antigen-presenting cells, thereby inhibiting T cell activation, produced in CHO cells Arcalyst in US, Rilonacept Regeneron in EU (rilonacept), dimeric	Regeneron Pharmaceuticals	Cryopyrin-associated periodic	2009 (EU)
Remicade (infliximab), chimeric mAb against TNF- α , produced in Sp2/0 cells	Janssen (Leiden, the Netherlands) MedImmune (Gaithersburg, MD,	Crohn's disease Prophylaxis of lower respiratory	1999 (EU) 1998 (US) 1999 (EU)	fusion protein with each monomer consisting of the ligand-binding domains of the human IL-1 receptor and the IL-1 receptor acces- sory protein along with the Fc region of human IgG-1, produced in CHO cells		syndromes (CAPS)	2008 (US) Withdrawn 2012 (EU)
Synagis (palivizumab) humanized mAb directed against an epitope		tract discoss coursed by					
Synagis (palivizumab) humanized mAb directed against an epitope on the surface of respiratory syncytial virus, produced in a murine myeloma cell line Zenapax (daclizumab), humanized mAb against the IL-2 receptor	USA) AbbVie Deutschland (Ludwigshafen, Germany) Roche (Welwyn Garden City, LIK)	tract disease caused by syncytial virus in children Prevention of acute kidney trans-		Nplate (romiplostim), dimeric fusion protein with each monomer consisting of two thrombopoietin receptor binding domains and the Fc region of human IgG-1, produced in <i>E. coli</i>	Amgen Europe	Thrombocytopenia	2009 (EU) 2008 (US)

NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 12 DECEMBER 2018

Table 1 Continued

Product

Orencia (abatacept), fusion protein that links the extracellular domain of human cytotoxic T-lymphocyte associated antigen-4 with modified Fc region of IgG1, produced in a mammalian cell line Amevive (alefacept), dimeric fusion protein consisting of the extracellular CD2-binding portion of human LFA-3 linked to the

region of human IgG1, produced in CHO cells Enbrel (etanercept), r TNF receptor-IgG fragment fusion protein produced in CHO cells. Same product as Lifmior (see above)

Ontak (denileukin diftitox), r IL-2-diphtheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, produced in E. coli

Gene therapy and nucleic acid-based

Tegsedi (inotersen), a 20-nucleotide single-stranded oligonucleotide manufactured by direct chemical synthesis Luxturna (voretigene neparvovec-rzyl), a live, nonreplicating adeno-associated virus genetically modified to express the huma RPE65 gene

Spinraza (nusinersen sodium), an 18-nucleotide antisense oligo-nucleotide manufactured by direct chemical synthesis Exondys 51 (eteplirsen), a chemically synthesized antisense oligo

nucleotide Imlygic (talimogene laherparepvec), an engineered herpes simple virus type 1 capable of producing GM-CSF Kynamro (mipomersen sodium), a chemically synthesized anti-

sense oligonucleotide Glybera (alipogene tiparvovec), human LPL gene housed in an engineered AAV1 vector

Macugen (pegaptanib sodium injection), a synthetic PEGylated oligonucleotide that specifically binds VEGF

Vitravene (fomivirsen), an antisense oligonucleotide

Engineered cell-based

Kymriah (tisagenlecleucel), autologous T cells genetically modifi to encode an anti-CD19 chimeric antigen receptor comprising a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains for 4-1BB (CD137) and **CD3**ζ

Yescarta (axicabtagene ciloleucel), autologous T cells genetically modified to express a chimeric antigen receptor comprising a murine anti-CD19 single-chain variable fragment (scFv) linked to CD28 and CD3 ζ co-stimulatory domains Strimvelis, autologous CD34⁺ cells transduced with an engi-

neered retroviral vector encoding the human adenosine deaminate sequence

Zalmoxis, allogeneic T cells genetically modified to express the herpes simplex thymidine kinase suicide gene and a truncated form of the human low-affinity nerve growth factor receptor gene

Data were collected from several sources (http://www.fda.gov/, https://www.ema.europa.eu/en). r, recombinant; rh, recombinant human; CHO, Chinese hamster ovary cell line; HEK, human embryo kidney cell line; BHK, baby hamster kidney cell line; PEG, polyethylene glycol; mAb, monoclonal antibody; tPA, tissue plasminogen activator; hGH, human growth hormone; FSH, follicle stimulating hormone; EOP, erythropoietin; IGF, insulin-like growth factor; BMP, bone morphogenetic protein; EGF, epidermal growth factor; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; VEGF, vascular endothelial growth factor; IFN, interferon; IL, interleukin; HPV, human papil-lomavirus; HBsAg, hepatitis B surface antigen; TNF, tumor necrosis factor; GLP, glucagon-like peptide; HER2, human epidermal growth factor receptor 2, CLL, chronic lymphocytic lowkers. leukemia.

	Company (location)	Therapeutic indication	Date approved
	Bristol-Myers Squibb (Uxbridge, UK)	Rheumatoid arthritis	2007 (EU) 2005 (US)
Fc	Astellas Pharma (Deerfield, IL, USA)	Moderate to severe chronic plaque psoriasis in adults	2003 (US) Withdrawn 2011
١,	Amgen (Thousand Oaks, CA, USA) Pfizer (Sandwich, UK)	Rheumatoid arthritis	2000 (EU) 1998 (US)
n 1	Eisai (Tokyo), Ligand Pharmaceuticals (San Diego)	Cutaneous T-cell lymphoma	1999 (US)
-	Ionis USA (London)	Hereditary transthyretin amyloi- dosis	2018 (EU)
an	Spark Therapeutics (Philadelphia)	Retinal dystrophy	2017 (US)
)-	Biogen Idec (Maidenhead, UK) Biogen (Cambridge, MA, USA)	Spinal muscular atrophy	2017 (EU) 2016 (US)
go-	Sarepta Therapeutics (Cambridge, MA, USA)	Duchenne muscular dystrophy	2016 (US)
lex	Amgen Europe Amgen	Melanoma	2015 (EU & US)
	Kastle Therapeutics (Chicago)	Familial hypercholesterolemia	2013 (US)
	uniQure (Amsterdam)	Lipoprotein lipase deficiency	2012 (EU) Withdrawn 2017
	Pfizer, PharmaSwiss Ceska Republika (Prague) Eyetech (Palm Beach Gardens, FL, USA),	Neovascular, age-related macular degeneration	2006 (EU) 2004 (US)
	Novartis Ophthalmics Europe (Farnborough, UK) Isis Pharmaceuticals (Carlsbad, California)	Cytomegalovirus retinitis in AIDS patients	1999 (EU) 1998 (US) Withdrawn 2002 (EU)
fied , d	Novartis (East Hanover, NJ, USA)	Acute lymphoblastic leukemia, large B-cell lymphoma	2017 (US)
y to	Kite Pharma (Santa Monica, CA, USA)	Large B-cell lymphoma	2017 (US)
ase	GlaxoSmithKline (Cork, Ireland)	Severe combined immunodeficiency	2016 (EU)
e	MolMed (Milan)	Hematopoietic stem cell trans- plantation, graft-versus-host disease	2016 (EU)